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HNSCC accounts for 7 percent of all new cancer occurrences. Despite currently available 
treatments, there continues to be a high mortality and recurrence rate in HNSCC.  Well over 50 
percent of all cancer patients receive chemotherapy as a standard treatment.  However, only 5 
percent of these cases have been shown to help with treatment of the disease.  Formerly, two 
options were available for drug testing: in vivo animal models, and in vitro two-dimensional 
models. While in vivo models remain the most representative, their use is burdened by high 
costs, time constraints, and ethical concerns.  2D models are simple to use and cost effective, 
although they have been shown to produce inaccurate data regarding chemotherapeutic drug 
resistance due to their 2D arrangement and altered gene expression.  Researchers for the past 
decade have been working to create 3D models that more accurately represent in vivo systems in 
order to evaluate chemotherapeutic efficacy and improve clinical outcomes.  In line with this 
  
agenda, novel 3D head and neck cancer models were created out of electrospun synthetic 
polymers seeded with either HN6 or HN12 cancer cells.  The models were then treated with 
chemotherapeutic drugs (either paclitaxel or cisplatin), and, after 72 hours, subjected to a live-
dead assay in order to determine the cytotoxic effects of the drugs.  2D cultures of HN6 and 
HN12 were also and subject to a WST-1 assay after 72 hours.  The results of the treated-scaffold 
assays were then compared to the results of the 2D culture assays, and, as predicted, the cancer 
cells in a 3D culture system proved to be more resistant to chemotherapeutic drugs.   
 
 The underlying assumption for this study being that a 3D culture system based on 
precisely defined structural parameters would provide a practical environment to screen 
therapeutics for anti-cancer efficacy. To prove this, 3D scaffolds of three different fiber sizes 
were developed by electrospinning different concentrations of Poly(L-lactic acid) (“PLLA”) 
(55mg/ml, 115mg/ml, and 180mg/ml) onto a mandrel that was perforated to allow for increased 
porosity.  The resultant small, medium, and large scaffolds were then subjected to concentrated 
hydrochloric acid (HCl) pretreatment in order to make them less hydrophobic.  Different fiber 
diameters represented different ECM environments for both HN6 and HN12.  It was proven that 
both cell types thrived best in small fibers (55mg/ml-115mg/ml) than in large fibers.  It was also 
reaffirmed through live-dead anlaysis of cells seeded on 3D scaffolds and treated with IC90 
values of cisplatin that the head and neck cancer cells were more resistant which is more 
representative to the 3D environment of cancer cells in vivo.  
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Chapter 1 
Introduction 
1.1. Background  
Annually, 650,000 people worldwide are newly diagnosed with head and neck cancer.  In the 
United States alone there were over 39,000 new cases of head and neck cancer and over 13,000 
deaths attributed to this disease in 2005.  Cancers of the head and neck include cancers of the 
oral cavity, pharynx, larynx, salivary glands, and nose/nasal passages.  Malignancies of the 
different cancers vary in terms of pathology and locations within the head and neck [1].  
 Mortality rates due to head and neck cancers have remained constant over several 
decades.  Despite advances in delivery of treatment and surgical reconstruction, mortality rates 
for this disease have not improved in the past 40 years.  Standard therapy today includes: 
radiation, surgery, and/or chemotherapy.  Five year survival rate is only about 40%, primarily 
due to metastasis [2].  Over time, head and neck cancers will metastasize. In other words, they 
will disseminate and colonize organs distinct from where they originated [3].  Cancers of the 
head and neck tend to metastasize to nearby lymph nodes, from where the cancer cells may 
travel to distant sites such as the lung and the liver.    
 Although there are a tremendous variety of malignant processes involved in head and 
neck cancers, over 90% of these cancers are squamous cell carcinomas (HNSCC) [2].  Squamous 
cells are thin, flat cells that form the surface of the eye, skin, various internal organs, the lining of 
hollow organs and ducts of some glands.  Head and neck cancers usually begin in the squamous 
cells that line the moist, mucosal surfaces in the head and neck such as the nose, mouth, and 
throat [4].   
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1.2. Prevention   
There are several causes attributed to HNSCC, but the strongest risk factors are alcohol 
and tobacco usage.  At least 75 percent of all head and neck cancers are caused by tobacco and 
alcohol, especially cancers of the oral cavity, oropharynx, hypopharynx, and larynx.  Non-
smokers and patients that drink little to no alcohol that have HNSCC may have, in some cases, 
been infected with cancer-causing types of human papillomavirus (HPV), especially HPV-16, 
particularly with cancers within the oropharyngeal region that involve the tonsils or the base of 
the tongue.  Incidences of oropharyngeal cancers caused by HPV have been increasing in the 
United States [4].  
Prevention of HNSCC is an important focus, so that drastic treatment measures can be 
avoided.  Prevention can be divided into primary, secondary, and tertiary prevention.  Primary 
prevention is cessation or avoidance of risk factor exposure such as alcohol and tobacco via 
education.  Secondary prevention is early detection, or seeking a physician as soon as there are 
any differences in health.  The tertiary prevention would be the reduction of complications, 
reducing the chance of further dysfunction including speech, dental, and swallowing problems 
[5].   
Primary prevention is the most effective way to avoid HNSCC because it targets the risk 
factors that cause cancers of the head and neck.  Avoiding these risk factors is an important way 
to avoid HNSCC altogether.  Extrinsic factors include external agents such as tobacco, alcohol, 
dietary, sunlight, and HPV.  Intrinsic factors are underlying circumstances that may predispose 
individuals to develop this malignancy.  These intrinsic factors include immune deficiency, iron-
deficiency anemia, and other genetic factors.  The main way to avert HNSCC is the prevention or 
cessation of tobacco.  Epidemiologic studies have shown that those who smoke cigarettes are 
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five to nine times more likely to develop oral cancer than nonsmokers; whereas this risk can 
increase to as high as 17 times for extremely heavy smokers [17].   
1.3. Treatment 
The current most common modalities for treating HNSCC are surgical excision, radiation 
therapy, and chemotherapy, or combinations thereof.  The location, stage, size, involvement of 
adjacent normal structures, and the available expertise all determine the modality or combination 
of treatments that should be used to treat HNSCC. Considering the head and neck are the most 
visible and noticeable portions of the human body, treatment options are considered thoroughly.  
Head and neck tumors have a profound effect on the daily life of patients when it comes to 
speech and swallowing.  Thus, the goal in treating these tumors is not only to cure the underlying 
malignancy but to do so with minimal effect on both function and aesthetics, in order to sustain 
the quality of life of the patient.  In order to achieve this goal, the standard treatment today is 
commonly a combination of radiation therapy and chemotherapy, as opposed to the severity of 
excision [1].  Radiotherapy and surgical techniques have resulted in an improved survival rate, 
although recurrence rates have remained high, necessitating other forms of treatment [6]. 
1.3.1. SURGICAL EXCISION  
Surgery for oral cavity and oropharyngeal cancers entails several different types of 
operations depending on the stage of cancer and where it is located.  These surgeries include: 
tumor resection (removal of entire tumor), Mohs micrographic surgery (cancers of the lip), 
glossectomy (removal of the tongue), mandibulectomy (removal of the jaw bone), maxillectomy 
(removal of hard palate), laryngectomy, neck dissection, dental extraction and implants, and 
finally reconstructive surgery is frequently needed to restore structure or function of affected 
areas.  Surgery contains many risks including but not limited to blood clots, infections, 
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complications from anesthesia, pneumonia and death.  The complications vary depending on the 
complexity of the procedure, but regardless, the patient will experience pain afterward that is 
primarily treated through medication.  In cancers of the head and neck, it is more common for 
the surgeries to be complex because the tumors may be large or strenuous to reach.  In these 
complex surgeries several side effects can occur including wound breakdown, infection, 
difficulty with eating and speaking, disfiguring of anatomy, or even death during or shortly after 
the procedure [7].   
1.3.2. RADIATION THERAPY 
Radiation therapy is a minimally invasive alternative to the severity of surgical excision 
of tumors.  Radiation therapy uses high-energy x-rays or particles to slow the growth rate or to 
destroy cancer cells.  It has several different uses when associated with oral and oropharyngeal 
cancers.  Radiation therapy can be used as the main treatment for small cancers.  Patients with 
larger cancers may require the combination of surgery and radiation therapy.  Post-surgery 
radiation therapy can be used as an adjuvant (additional treatment) in order to kill any small 
remnants of cancer that may have not been removed during surgery.  Radiation therapy can also 
be used as a neoadjuvant treatment, or before surgery, to shrink tumors.  Additionally, radiation 
therapy has been successful in cases to relieve pain, bleeding, swallowing difficulties, and 
metastases.  Any of these cases may require the merging of radiation therapy and chemotherapy.  
Radiation of the mouth and throat can cause several side effects including pigment changes of 
the skin, hoarseness of the voice, loss in sense of taste, and redness or soreness of the mouth and 
throat (mucositis).  Fortunately, the previously listed side effects are commonly in existence for a 
short period of time.  Such side effects are normally more severe in patients that are receiving 
chemotherapy simultaneously [7].   
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1.3.3. CHEMOTHERAPY 
It is desirable to treat HNSCC with minimal invasiveness, to sustain the quality of life of 
the patient. Considering the severity of the common modalities used to treat HNSCC, 
chemotherapy is a justifiable option.  Chemotherapy is the use of anti-cancer drugs taken orally 
or given intravenously.   There are a few different scenarios where chemotherapy may be used, 
including in combination with radiation therapy or surgery, or as a substitute for surgery as the 
main treatment for some cancers.  Adjuvant chemotherapy is the combination of 
chemotherapeutic drugs with radiation therapy post-surgery, in order to kill any remaining 
cancer cells.  Neoadjuvant or induction chemotherapy refers to the use of chemotherapy drugs 
(sometimes with radiation) to shrink larger cancers prior to surgery. This can lead to a less 
radical surgery and a decrease in serious surgical side effects. Last, chemotherapy may be used 
to treat cancers that are too large and have metastasized too widely to be removed by surgery.  In 
this case, the drug is used to slow the growth of the cancer and help relieve any symptoms the 
cancer may be causing [7].   
The primary goal of chemotherapy drugs is to attack cells that are dividing quickly, 
which is why they work effectively against cancer cells.  However, other cells in the body that 
also divide quickly may be affected, such as bone marrow, the lining mucosa of the mouth and 
intestines, and hair follicles.  Because of this, several side effects are attributable to 
chemotherapeutics.  Side effects include mouth ulcers, hair loss, nausea and vomiting, a decrease 
in appetite, diarrhea, and a low blood count due to effects on the bone marrow.  Low blood 
counts can lead to increased risk of infections, easy bleeding or bruising, and fatigue.  Many, if 
not all, of these side effects improve once treatment is stopped [7].     
1.3.4. FREQUENT FAILURE OF CHEMOTHERAPY 
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 Well over 50 percent of all cancer patients receive chemotherapy as a standard treatment.  
However, only 5 percent of these cases have been shown to help with treatment of the disease.  
Chemotherapeutic drugs have been found to be highly successful in eliminating some cancer 
types. However, an increase in survival rates for the majority of cancer patients through 
chemotherapy has not been proven.  Chemotherapeutic drugs are effective in killing cancer cells; 
unfortunately the drugs are simultaneously killing healthy normal cells.  Killing of healthy 
normal cells results in a depressed immune system causing the cancer patients to be susceptible 
to several other ailments, as previously mentioned.  It is true that chemotherapeutic drugs cause 
shrinkage in tumors, but this does not necessarily translate to long-term survival rate in patients 
[36].   
 Chemotherapy treatment can lead to death of most of the tumor cells (drug-sensitive) 
although some of them (drug-resistant) are able to survive and grow again.  Cancer cells can 
develop the ability to become resistant to many different types of chemotherapeutic drugs.  This 
process can occur through an increased efflux of drug, enhanced repair/increased tolerance to 
DNA damage, high antiapoptotic potential, decreased permeability, or decreased enzymatic 
deactivation [35].  
 HNSCC falls into the category of cancers that are normally unable to be treated with 
chemotherapy alone.  As stated previously, chemotherapy is typically combined with radiation 
therapy, and has been reserved for those with advancement or recurrent stages of the disease.  
Chemotherapeutic drugs have been successfully used to control the progression of the tumor, 
although this treatment has not been able to translate to overall long-term survival.  As 
mentioned formerly, survival rate for HNSCC has remained static at 40 percent for several years 
despite advancements in treatment [37].  Because of the failures in chemotherapy treatment, an 
 7 
 
importance is placed on pre-testing the chemotherapeutic drugs in vitro.  Being able to treat 
HNSCC in vitro allows for a safer setting to test the efficacy of the drug.  
1.4. HNSCC Models 
 Cancer is considered to result from the accumulation of multiple genetic aberrations that 
transform cells, permitting their abnormal growth, proliferation, and metastasis.   In order to 
research the complexity of the disease, representative cancer models are simulated in a 
laboratory setting.  Multiple models of cancer have been described in the literature, including 
cancer cells in culture and genetically modified mice [8], and these have allowed significant 
enhancements of treatments. 
1.4.1. IN VIVO HNSCC MODELS 
 In vivo models of cancer have revolutionized the ability to study gene function in cancer 
pathogenesis, with mice being commonly used.  Mice are advantageous as a model system due to 
the fact that they are small in size, inexpensive to maintain, they reproduce rapidly with large 
litters, and are easily genetically manipulated.  A mouse model may be used for several different 
cancer research purposes, including gene function validation, identification of novel cancer 
genes and tumor biomarkers, or anticancer drug testing [9].      
 Despite some of the limitations that may arise with in vivo growth of a tumor, there is no 
current technology or in vitro assay that can predict the activity of antineoplastic drugs or 
demonstrate the tumorigenic and metastatic properties of tumors as accurately as xenograft 
animal models [10].  However, the testing of animal models can become expensive, time 
consuming, and have ethical concerns [22].  
1.4.2. IN VITRO HNSCC MODELS 
 Immortalized cell lines derived from HNSCC tumors are an in vitro system that enables 
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research into the molecular, biochemical, genetic, and immunological properties of head and 
neck cancer.  There are several advantages when using cell culture, such as sample homogeneity, 
cost, and the lack of legal and ethical issues associated with animal experimentation.  The 
process of establishing HNSCC cell lines over time has proven to be challenging due to 
fibroblast overgrowth, long quiescent periods before passaging the cells, and primary and 
secondary cultures being dependent on feeder layers.  Several different technical improvements 
have taken place in order to make successful permanent culture of HNSCC cell lines more 
feasible.  Therefore, more than 300 reported HNSCC cell lines have been developed, which is 
considerably more than cell lines derived from breast, colon, and prostate cancers [10].  
 Cancer cell cultures are typically grown as monolayer cells on polystyrene plastic.  
Although, some models introduce a three-dimensional (3D) setting for the cancer cells to grow, 
which more accurately represents tumor cell characteristics such as drug response or metastatic 
potential [10].  
1.5. Cell Sources For In Vitro Models  
1.5.1. EXTRACELLULAR MATRIX OF HNSCC 
The macromolecules that make up the extracellular matrix (ECM) of HNSCC are 
primarily proteins and polysaccharides secreted locally and assembled into an organized 
meshwork.  This meshwork of proteins and polysaccharides works closely with the surface of the 
cell that produces them [14]. The ECM associated with epithelial structures is mainly composed 
of laminin, collagen, fibronectin, and glycosaminoglycans.  This was once viewed as the 
architectural support of the cells, but it is now understood that the ECM is a major regulator of 
cell activity.   The molecules that make up the ECM act as ligands for integrins which, in turn, 
support tissue development, tissue maintenance, wound healing, and oncogenesis.  Changes in 
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the composition of the ECM, altered expression, secretion, or processing, directly impacts 
oncogenic development, hyperplastic growth, and tumor development [15].   
1.6. Electrospinning 
 Electrospinning is a commonly used technique within the field of tissue engineering.  The 
process of electrospinning allows for the engineering of 3D scaffolds that can support cell 
growth and proliferation.  Electrospinning is an attractive technique for nanofiber fabrication 
which can be used to produce fibers ranging from several micrometers to about 100 nm or less.  
Several different natural substances are able to be electrospun such as collagen, silk fibroin, 
chitosan, gelatin, and a wide range of biodegradable polymers [28].  Electrospun scaffolds are 
used as a framework for host cells to populate and deposit ECM components to eventually 
replace the targeted organ [16].  The host-appropriate cells are then able to proliferate and 
occupy the void spaces with their own extracellular matrices within the scaffold.  With the 
process of electrospinning, properties of the engineered scaffold are able to be manipulated for 
ideal cell viability, proliferation, migration, and differentiation.  Some key characteristics of an 
ideal scaffold are appropriate levels and sizes of porosity for cell migration; sufficient surface 
area and surface chemistries to encourage cell adhesion, growth, migration, and differentiation; 
and a degradation rate that closely matches the regeneration rate of the desired natural tissue 
[16].   
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 Electrospinning is a mesh of synthetic or natural material consisting of fibers with 
ranging diameters.  These materials are biocompatible in order to eliminate concerns regarding 
unfavorable immune responses or disease transmission.  The principal elements needed for 
electrospinning are a polymer source, a high voltage supply, and a collector.  With the input of 
the high voltage supply, an electric potential occurs between the polymer source and the 
collector.  Charge then accumulates and is forced to the surface of an emerging polymeric 
droplet, through a syringe connected to a pump, at the end of a metal needle.  The force of the 
electric field becomes larger than the cohesive force of the solution, which is predominantly 
surface tension, and an electrically charged jet of polymer containing solution erupts.  This jet 
then migrates towards the collector plate and is elongated by electrostatic interactions between 
charges on nearby segments of the same jet.  Through this electrostatic migration, the solvent 
evaporates and the jet solidifies into a fiber as can be seen in Figure 1.1 [16]. 
Figure 1.1: Schematic diagram of set up of electrospinning apparatus [38]. 
 
 It is advantageous to fabricate a synthetic ECM through tissue engineering because it is 
chemically pure.  In other words, the ECM contains no uncharacterized growth factors or other 
contaminants when made with synthetic material, such as Polylactic Acid (PLA), which makes 
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the scaffold easy to engineer chemically.  This provides the possibility for elegant cross-linking 
and multiple modification options, which allows the scaffold to be used in a variety of ways such 
as artificial tissues, surgical devices (sutures, clamps, etc.), drug delivery devices, and drug 
testing models.  The main disadvantage of synthetic matrices is that they are not as biologically 
relevant as naturally derived matrices therefore they may not contain the signaling molecules and 
sequences that native ECM provides [22].    
In the field of tissue engineering, bio mimicry has been the major impetus for biomedical 
applications.  Since the natural ECM is composed of fibrillar collagens that are approximately 50 
to 150 nm in diameter, biomimicking similar features has led to the engineering of nanoscaffolds 
of the same dimensional scale.  Studies have shown that nano-dimensional surfaces on tissue 
engineered scaffolds lead to enhanced cell adhesion and proliferation over micro-dimensional 
surfaces.  It has also been shown that cells organize well around fibers with diameters smaller 
than the diameter of the cells.  Better cell attachment occurs in smaller diameter scaffolds, as it is 
thought that the smaller surface area localizes more absorption of adhesion proteins.  Smaller 
fiber diameters have been found to have a higher cell growth rate because of larger surface area-
to-volume ratio that allows for more cell growth factors to bind to the fibers.  It is also possible 
that scaffolds with smaller diameters are more pliable, which allows cells to migrate within the 
scaffold with less force [28].   
1.6.1. POLY(LACTIC) ACID  
 Poly(lactic) acid (PLA) is known as one of the most promising biodegradable polymers 
used for commodity applications.  PLA is a thermoplastic, aliphatic polymer that is derived from 
renewable resources such as corn starch and sugar cane via fermentation and ring-opening 
polymerization.  The biodegradability and biocompatibility of PLA are sufficient enough for the 
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polymer to have been used for three decades in biomedical applications.  PLA has been used in 
biomedical devices including sutures, clips, tissue engineering scaffolds, and drug delivery 
devices [20].  With breakthroughs in biotechnology, within the past decade high quality PLA has 
been able to be mass-produced and commercialized for targeted, low-cost fiber, insulation, and 
packaging applications.  Other than the drive of cost, PLA is a desired polymer in biomedical 
applications because of the ability to tailor its physical properties.  The physical properties that 
are able to be modulated in PLA are molecular weight, molecular topology, and mixing ratio of 
three stereoisomers, L-lactide, D-lactide, and meso-lactide, during synthesis [18].   
One drawback of PLA is that its degradation rate through hydrolysis can be very slow, 
which may be detrimental for biomedical purposes.  The polymer is also very brittle, with less 
than 10 percent elongation at break, which makes PLA unsuitable for demanding mechanical 
performance applications.  The most unfavorable quality of PLA when it comes to tissue 
engineering is its strong hydrophobicity.  Because of its strong hydrophobicity, PLA can elicit an 
inflammatory response from host tissues, which in turn educes a low affinity with cells when 
using tissue engineering materials [20]. 
1.6.2. POLY(L-LACTIC ACID)  
 As discussed previously, PLA is derived from lactic acid that exists as two enantiomers: 
L- and D-lactic acid (PLLA and PDLA, respectively).  The degradation rate half life of PLLA is 
about six months to two years [20].  Specifically, PLLA is used similarly to PLA for several 
tissue engineering procedures.  Table 1.1 shows the variations between the different physical and 
chemical properties of PLA.  PLLA is a semicrystalline polymer, where crystal polymorphism 
has been studied extensively because mechanical properties of the polymer depend heavily on 
crystal structure [19].   
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Table 1.1 Selected physical and chemical properties of PLLA [20].  
Properties PDLA PLLA PDLLA 
Solubility  All are soluble in benzene, chloroform, acetonitrile, 
tetrahydrofuran (THF), dioxane etc., but insoluble in ethanol, 
methanol, and aliphatic hydrocarbons 
Crystalline structure Crystalline Hemicrystalline Amorphous 
Melting temperature (Tm)/ °C ~180 ~180  Variable  
Glass transition temperature 
(Tg)/ °C  
50-60 55-60 Variable  
Decomposition 
temperature/°C  
~200 ~200  185-200  
 
Elongation at break/ (%) 20-30 20-30 Variable  
Breaking strength/ (g/d) 4.0-5.0 5.0-6.0 Variable  
Half-life in 37°C normal 
saline 
4-6 months 4-6 months 2-3 months  
 
1.6.3. MECHANICAL PROPERTIES OF BIOMATERIALS 
 Tissue engineering uses the method of electrospinning to produce scaffolds composed of 
biomaterials that mimic native tissue as much as possible.   One property of great importance 
when considering the imitation of native tissue is the mechanical properties of the biomaterial.  
Mechanical properties can help mirror intrinsic characteristics of the tissues such as its 
crystallinity and structure of its ECM fibers.  A few distinct parameters that are recognized 
through mechanical testing of scaffolds are strength, peak stress, strain, and Young’s modulus.  
Strength is measured as the force applied to the scaffold over the cross-sectional area of the 
scaffold which is otherwise defined as stress.  Strength is measured in N/m^2 or Pascals (Pa).  
Peak stress is the maximum amount of stress a solid material can withstand, this parameter can 
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conveniently be used to compare with other biomaterials.  Strain is a deformation of solid 
material under a known stress.  In short, strain is the ratio between initial shape and deformation 
of an object which makes strain a unit less measurement.  The testing is done under a uniaxial 
tensile loading which causes a longitudinal deformation.  The stretching is done under a known 
stress where the ratio between the changes in length to the final length prior to failure is 
determined.  This uniaxial stretching is classified as stress vs. strain which is described by the 
numerical constant known as tensile or Young’s modulus.  This numerical constant describes the 
elastic properties of isotropic material undergoing tension or compression uniaxially.  Young’s 
modulus is a measure of the ability of a material to withstand changes in length under tension or 
compression and is equal to the longitudinal stress divided by the strain, within the elastic range 
of the material [21].  Since Young’s modulus is the ratio of stress (Pa) and strain (unitless) the 
constant is calculated in Pa.  Quantifying the information from mechanical testing biomaterials is 
a crucial aspect of tissue engineering.  With these data, scaffolds can more efficiently be 
engineered to mimic, or even improve, the mechanical functions of the native tissues [6, 19]. 
1.7. Drug Testing in HNSCC  
 Traditionally, chemotherapeutic drugs have been tested on tumor cells that are cultured as 
two-dimensional (2D) monolayers on plastic cell culture plates.  Current 2D monolayer drug 
testing may not accurately mimic 3D arrangements where cancer cells reside in vivo.  Because of 
these artificial conditions, there are large changes in gene expression compared to tumors in vivo 
including: signal transduction, cellular movement, cell-to-cell signaling, cellular growth, and 
morphology.  Several laboratories have reported that differential gene expression between 2D 
and 3D arrangements leads to inaccurate data regarding predicted responses of cancer cells to 
chemotherapeutics [22, 23].   
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 The utilization of 3D cell culture models has become increasingly popular because these 
structures resemble in vivo structures with an improvement in cell-to-cell and cell-to-matrix 
contact.  As described previously, one of the most common forms of 3D cell culture system is a 
prefabricated scaffold.  Mechanical properties of the scaffold and the ECM of tumor cells 
cultured in a 3D environment affect behavior and gene expression of cancer cells.  The transition 
from 2D to 3D has shown an elevation in chemoresistance to anticancer drugs when tested on 
cells cultured in a 3D model.  It has been hypothesized that the 3D model allows for pro-survival 
signaling and an upregulation of genes conferring drug resistance and may also limit diffusion of 
drugs.  It is also apparent that tumor cells adopt a different morphology in 2D compared with 3D, 
as in 3D the tumor cells are more clustered and show a more rounded shape.  Studies have shown 
that tumor cells express different genes in 3D such as an increase in glycolytic enzymes and 
other key regulators.  Genes that show elevated expression in 3D cancer models include vascular 
endothelial growth factor (VEGF) which contributes to angiogenesis, and genes responsible for 
cell migration and invasion including Rho GTPases and focal adhesion kinase (FAK) [22, 23].  
Testing chemotherapeutics on tumor cells cultured in 3D cancer models may better recapitulate 
the drug sensitivity of these tumors in vivo.  There are several chemotherapeutic drugs that are 
routinely used for treatment of HNSCC, but for our study we have chosen to work with two well-
established chemotherapeutic drugs.  Both of these drugs have been used clinically for many 
cancer types, including HNSCC, but have been known to elicit resistance in clinical applications 
[6].    
1.7.1. PACLITAXEL 
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 One of the well-established chemotherapeutic drugs chosen for this study is Paclitaxel 
(Taxol) [23].  Paclitaxel is an off-white crystalline powder (C47H51NO14) with a molecular 
weight of 853.9.  It is highly lipophilic, therefore insoluble in water, and melts around 216-
217°C [31].   
Figure 1.2: Chemical structure of Paclitaxel [31]. 
Paclitaxel is a compound with antineoplastic activity, inhibiting or preventing the growth 
and spread of tumors or malignant cells, that was extracted from the Pacific yew tree Taxus 
brevifolia.  This chemotherapeutic functions by binding to tubulin and inhibits the disassembly 
of microtubules which in return results in the inhibition of cell division.  Essentially, Paclitaxel is 
able to prevent depolymerization by stabilizing and rearranging the cytoskeleton of the cancer 
cells and arresting them in G2 or M phase of the cell cycle.  This procedure causes the affected 
cells to either undergo apoptosis or remain in a growth-arrested state [6].  The induction of 
apoptosis occurs when Paclitaxel binds to and blocks the function of the apoptosis inhibitor 
protein Bcl-2 (B-cell Leukemia 2) [23].  According to prior studies done in this laboratory, 
HN12 cells cultured in 2D have been shown to be sensitive to therapeutic doses of Paclitaxel [6].    
 Paclitaxel has been approved to be used either alone or in combination with other drugs 
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to treat AIDS-related Kaposi sarcoma, breast cancer, non-small cell lung cancer, ovarian cancer, 
and other types of cancer including HNSCC [23].  Intravenous injection of Paclitaxel causes a 
large decrease in the number of white blood cells, which results in an increased susceptibility to 
infections.  Side effects include: pain, redness, swelling around injection site, weakness, muscle 
or joint pain, nausea, vomiting, diarrhea, stomach pain, mouth ulcers, hair loss, numbness, 
burning, tingling in the hands or feet, pale skin, excessive tiredness, unusual bruising or 
bleeding, chest pain, slow or irregular heartbeat, fainting, and blistering or peeling skin [24].   
1.7.2. CISPLATIN 
Cisplatin, also known as Platinol or cis-diamminedichloroplatinum(II)
 
(CDDP), is one of 
a series of platinum-compound chemotherapeutic drugs which are informally referred to as 
platins [25].  Cisplatin is an alkylating agent and attaches an alkyl group to the guanine base of 
DNA at the number seven N atom of the purine ring.  By cross-linking the DNA, cisplatin 
inhibits DNA repair and DNA synthesis in cancer cells [26].  Since cancer cells have the 
tendency to proliferate faster with less error-correcting than healthy cells, cancer cells are 
considerably more sensitive to DNA damage [25].   
Cisplatin is a heavy metal complex with a central atom of platinum surrounded by two 
chloride atoms and two ammonia molecules in the cis position.  Cisplatin comes in a crystalline, 
white powder form with a molecular formula of PtCl2H6N2 and a molecular weight of 300.05.  
This drug is soluble in water or saline at 1 mg/mL and dimethylformamide at 24 mg/mL with a 
melting point of 207°C [32].   
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Figure 1.3: Chemical structure of Cisplatin [32]. 
 Cisplatin has been used to treat cancers of the bladder, ovaries, testicles, and other types 
of cancer such as HNSCC.  This chemotherapeutic drug is given intravenously for at least one 
hour and the dosage is dependent on the type of cancer being treated, the size of the patient, and 
renal health [26].  As with several other chemotherapeutics, cisplatin is potent enough to kill 
normal cells which can result in several side effects that may last for months or even years after 
medicinal use [25].   With coordination complexes of platinum, the main dose-limiting side-
effects of cancer treatment are neurotoxicity and peripheral neuropathies.  This results in 
numbness of the hands and/or feet as well as a tingling sensation in any of these extremities.  
Several other side effects may exist due to cisplatin including kidney damage, decreased blood 
levels of magnesium, potassium, and calcium, nausea, vomiting, low white blood cell count, low 
platelet count, increased bleeding, low red blood cell count (anemia), changes in taste, and fetal 
changes if pregnant [26].   
1.8. Hypothesis and Specific Aims 
1.8.1. HYPOTHESIS 
A 3D culture system based on precisely defined structural parameters provides a practical 
environment to screen therapeutics for anti-cancer efficacy. 
1.8.2. SPECIFIC AIMS 
 Specific Aim 1: Test sensitivity of HNSCC cells grown in 2D culture to cisplatin and 
paclitaxel.   
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 Rationale: HNSCC accounts for 7 percent of all new cancer occurrences.  Despite 
currently available treatments, there continues to be a high mortality and recurrence rate in 
HNSCC [6].  Although there have been recent advances in delivery of treatment and surgical 
reconstruction, mortality rates for HNSCC have not improved in the past 40 years.  Currently, 
anti-cancer chemotherapeutics are routinely tested on 2D monolayer cell cultures.  It has been 
shown in previous studies that tumor cells grown in 2D monolayer culture are much more 
sensitive to chemotherapeutic drugs [6, 27].  It is important to determine drug sensitivity of 
HNSCC cells in monolayer culture, so that their response in 3D environment can be investigated.   
 
Specific Aim 2:  Construct a 3D culture system of different fiber dimensions by 
electrospinning to test the effect of fiber diameter in cell growth and drug sensitivity.   
Rationale: The field of tissue engineering has developing materials to reconstruct 
damaged or missing tissues or organs.  Tissue engineering has not normally focused on creating 
tumor models for in vitro evaluation of drug efficacy.  For this purpose, we propose to use 
electrospinning of PLLA to form scaffolds of three different fiber diameters: small, medium, and 
large.  We suggest that different fiber diameters will elicit different cellular characteristics and 
therefore represent different 3D tumor models.  From the three fiber sizes, we would be able to 
decide which fiber dimension would provide the best cell infiltration, cell survival, and overall 
drug testing apparatus.   
 
Specific Aim 3: Test the effect of varying fiber diameter on HNSCC drug sensitivity in 
3D culture. 
 Rationale: Several studies have shown that anticancer drugs do not work as effectively 
in vivo as they do on a 2D cell monolayer.  Discrepancy in drug efficacy is due, in part, to the 3D 
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nature of tumors as opposed to the 2D nature of monolayer culture.  It is known that cells grown 
in 3D have different cell surface receptor expression and proliferation, cell density, extracellular 
matrix synthesis, and metabolic functions than cells grown in 2D monolayer.  It has been 
suggested that many important signals, key regulators, and tissue phenotypes are lost when cells 
are cultured in 2D substrates (culture plates) instead of a 3D environment.  In order to more 
realistically assess drug efficacy prior to testing in animal models or patients, it is important to 
develop an in vitro model of a tumor that would resemble an actual tumor [26].   
Different fiber diameters represent different ECM environments for the cells, including 
mechanical properties, porosity, possibilities for angiogenesis, along with other characteristics of 
the microenvironment.  We hypothesize that different fiber diameters will result in differences in 
infiltration, migration, and adhesion of the cancer cells.   
Chapter 2 
Methods and Materials 
2.1. Cell Culture 
2.1.1. HN6, HN12, HN12-YFP CELL LINES 
 A model HNSCC cell line frequently used is the WSU-HN12, also known as HN12, 
which was established at Wayne State University in 1994.  The HN12 cell line was derived from 
metastatic tumor from lymph nodes [6].  Over 50 studies indexed in PubMed characterize these 
cells as representative cells of HNSCC in a variety of drug response as well as mechanistic 
studies [11].  The majority of the studies were performed in 2D cultures, some of the studies 
included injecting the cells into nude mice representing in vivo models.  Each of these studies 
found that HN12 cells are highly proliferative, motile, and tumorigenic in vivo.  HN6 cell lines, 
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which are less commonly used, were derived from primary metastatic HNSCCs which have been 
described previously [48].  
HN12 and HN6 cell lines were propagated in Dulbecco’s Modification of Eagle’s 
Medium (DMEM) (Life Technologies, Grand Island, NY) supplemented with 10% (v/v) fetal 
bovine serum (Fisher Scientific, Pittsburgh, PA), 100 units/ml of penicillin and 100 μg/ml 
streptomycin (Thermo Fisher, Asheville, NC), and 1 mM sodium pyruvate (Thermo Fisher, 
Asheville, NC).  All cells were incubated at 37 °C, 10% CO2 in a humidified environment [6, 
30].  HN12 cells were nucleofected with yellow fluorescent protein (YFP) plasmids in order to 
portray appropriate fluorescent microscopy images and were done in the laboratory prior to this 
study [6].  
2.2. Cytotoxicity Testing of Monolayer Cells 
2.2.1. CHEMOTHERAPEUTIC TREATMENT  
 Both HN12 and HN6 cells were treated with each of the chemotherapeutic drugs.  
Cisplatin and paclitaxel (Sigma-Aldrich, St. Louis, MO) both came in powdered form, which 
needed to be solubilized for use.  Paclitaxel was solubilized in DMSO at 50 mg/ml and then 
stored at -20 °C.  Cisplatin was solubilized in phosphate buffered saline (PBS) at 10 mg/ml and 
stored at 4 °C.   
 Each cell line was tested with each drug.  Prior to the cytotoxicity tests, cells were 
trypsinized and counted using an automated cell counter (Nexcelom Bioscience, Lawrence, MA).  
Cells were then seeded at 5 x 10
3
 cells per well in 96 well tissue culture plates.  The cells were 
then allowed to attach and proliferate for 24 hours in complete medium (DMEM/10% FBS).  
Cells were cultured in triplicate for each condition.  Increasing concentrations of either paclitaxel 
or cisplatin were added to each cell type and were compared to the control samples, which were 
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cells exposed to vehicle alone (DMSO or PBS).  The cells were then allowed to grow for 72 
hours prior to assay.   
2.2.2. WST-1 ASSAY 
 In order to determine the cytotoxic effects of the chemotherapeutic drugs, the WST-1 
assay was used.  WST-1 assay is a non-radioactive, colorimetric assay that quantifies cell 
viability.  When compared to other cytotoxicity assays such as MTT, MTS, and XTT; WST-1 is 
advantageous because it is a ready-to-use reagent, no radioactive isotopes are used, there are no 
washing steps, and no additional reagents needed.  The WST-1 assay is based on the cleavage of 
tetrazolium salt WST-1 to form formazan-class dyes by mitochondrial succinate-tetrazolium 
reductase.  Therefore this process only occurs in viable cells, and is quantified by absorbance at 
420-480 nm using a plate reader (BioTek Instruments, Winooski, VT).   This assay is highly 
sensitive and has the ability to detect low cell numbers as well as being able to process a large 
number of samples in a multi-well format.  In addition, WST-1 is water-soluble; therefore, the 
assay protocol is simplified because there is no need for organic solvent washing in between 
steps [29].   
Figure 2.1: Chemical structure of tetrazolium salt cleaved to form formazan dye [29]. 
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 The IC90 for 2D culture of HN12 and HN6 cells in monolayer was determined by using 
the WST-1 assay.  Cells were seeded and treated as previously described.  After 72 hours of drug 
treatment, media/chemotherapeutic mix or control was aspirated from each well.  A ten fold 
dilution of media to assay solution was made in order to pipette into each well seeded with cells.  
Thus, 90 μl media and 10 μl of assay were pipetted into each well so that 100 μl of assay mixed 
with media could be added to each well.  The cells seeded with WST-1 and media mixture were 
then incubated for 40 minutes in order to allow formation of formazan dye.  
2.3. Scaffold Fabrication 
2.3.1. ELECTROSPINNING PARAMETERS 
 
 Electrospinning was performed in order to produce scaffolds for cell seeding as 
previously described.  Polymer was spun onto an air impedance mandrel as seen in Figure 1.1.  
The air impedance mandrel was designed to allow for air to be pumped through the small holes.  
Air pressure is induced during electrospinning in order to generate porosity throughout the 
scaffold with the goal of increasing cell infiltration after seeding.  For our experiments, air was 
not used, although the holes alone gave the possibility for increased porosity, and the same 
mandrel was used for consistency.  The mandrel was set eleven inches away from an 18 gauge 
blunt needle tip in order to allow enough room to fabricate the appropriate sized jet streams and 
produce the precise sized fibers.  A positive voltage of 25 kV was applied to the metal needle tip 
in congruence with an aluminum sheet grounded behind the spinning mandrel.  The mandrel 
spun at 500 revolutions per minute while the polymer solution was pumped out of the needle at a 
rate of 4 ml/hr.  All parameters were kept consistent for each scaffold fabricated in order to 
ensure consistency.   
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Figure 2.2: Air impedance mandrel used during electrospinning. 
 
2.3.2. PLLA  
 
PLLA (Sigma-Aldrich, St. Louis, MO), with a viscosity of ~2.0 dL/g, was dissolved in 
1,1,1,3,3,3 Hexafluoro-2-propanol (HFP) at specific concentrations.  PLLA was mixed and 
dissolved in HFP under the hood for a period of 24-48 hours to ensure the entire polymer was 
solubilized.  Concentration of polymer to volume of solvent was directly correlated to the fiber 
diameter that was generated for each scaffold.  
2.3.3. SCANNING ELECTRON MICROSCOPY 
 
 Dry scaffolds were generated by electrospinning and their morphology was evaluated by 
electron microscopy.  Dry scaffold samples were gold sputter coated and imaged with a JEOL 
JSM-5610LV scanning electron microscope (SEM) in the Nanomaterials Core Characterization 
facility at Virginia Commonwealth University.  Diameters and pore sizes were determined using 
NIH ImageJ (http://rsbweb.nih.gov/ij/) from 100 randomly chosen fibers and pores in each SEM 
image.  Average fiber diameters were calculated from these 100 randomly chosen fibers from 
each scaffold in order to assure that the fiber sizes are consistent among each of the labeled 
small, medium, and large fiber diameter scaffolds [6, 30].   
2.3.4. MECHANICAL TESTING 
 As previously described in section 1.6.3., uniaxial tensile testing was performed on each 
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electrospun scaffold.  The three different scaffolds, containing different fiber diameters, were 
punch into dog-bone shaped samples (overall length of 20 mm, 2.67 mm at the narrowest point, 
gauge length of 7.5 mm, n=9).  This type of tensile testing was performed using an MTS Bionix 
200 testing system with 100 N load cell (MTS Systems, Eden Prairie, MN).  Samples were 
pulled into tension uniaxially, along the longest axis of the samples until failure at a rate of 
10mm/min (1.33/min strain rate).  Calculations and readings of peak stress, modulus, energy at 
break, and strain at break were done through TestWorks version 4 [6].  
2.3.5. PORE SIZE AND POROSITY 
   The pore size and porosity of the scaffolds were measured using NIH Image J 
(http://rsbweb.nih.gov/ij/).  Three scaffolds of each fiber size were engineered and from each of 
these scaffolds, three samples were SEM imaged.  Therefore, for each fiber size scaffold, nine 
total images were taken from three different scaffolds in order to ensure consistency.   The SEM 
images were then assessed using NIH Image J by converting the images to binary and finding the 
edges of the fibers.  Particles were analyzed with a binary, circulatory measurement of 0.01-1.00.  
By inputting this data, the software was able to calculate the shape of the pores.  From here the 
pore sizes were calculated as well as the percentage of porous area (porosity).   
2.3.6 STATISTICAL ANALYSIS 
 
 All quantitative data between the small fiber, medium fiber, and large fiber diameter 
scaffolds were compared using a one-way anlaysis of variance (ANOVA) with p<0.05 
considered to be statistically significant. When ANOVA analysis resulted in statistically 
significant differences, the Tukey-Kramer test was performed to determine which data sets were 
significantly different.  All quantitative data are presented with the standard error of the mean 
(s.e.m.).   All statistical analysis was done using GraphPad Prism software [6].   
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2.4. Seeding Cells onto Fabricated Scaffolds 
 
2.4.1. ACID PRETREATMENT  
 
 As described previously, PLLA is a very hydrophobic polymer which is less than ideal 
for biocompatibility.  Studies have shown that acid pretreatment of scaffolds can improve the 
biocompatibility of hydrophobic polymers such as PLLA [33].  If scaffolds are subjected to 
concentrated hydrochloric acid (HCl) pretreatment the surface properties of the scaffolds are 
altered as well as the charge characteristics of electrospun PLLA.  HCl pretreatment can be used 
to manipulate hydrophilic nature of the polymer and improve cellular adhesion.  It has been 
hypothesized that improvements in hydrophilicity and adhesion are due to hydrolysis.   
Therefore, scaffolds were initially disinfected in 70% ethanol for ten minutes and then 
rinsed three times in purified water (Millipore Corporation, Billerica, MA) under agitation for 
ten minutes.  After water agitation, the scaffolds were then placed in 11.7 M HCl for five 
minutes.  After immersion in HCl, it is important to make sure that the scaffolds return to a 
neutral pH before seeding so that the cells are able to survive in a biocompatible environment.  
To achieve this, the scaffolds were rinsed in PBS for ten minutes three times with agitation, until 
the pH is returned to a neutral state by testing with pH strips (pHydrion Papers, Micro Essential 
Laboratory, Brooklyn, NY).  The scaffolds were then placed in media for two hours prior to 
seeding cells [33].   
2.4.2. CELL SEEDING 
 
 Scaffold disks were punched out from a larger sheet of electrospun PLLA using 6 mm 
scaffold biopsy punches (Picu Punch, Ft. Lauderdale, FL).  50 μl of 70% ethanol was pipetted 
into each well in order to disinfect scaffolds prior to seeding.  All cell types were seeded 
identically at a density of 1x10
4
 cells and scaffolds were anchored by 6mm diameter cloning 
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cylinders (Pyrex Corning Incorporated, Corning, NY).  Cells were allowed to grow for 7 and 14 
days and were imaged using a fluorescence microscope at both time points to ensure/confirm 
sufficient cell attachment and infiltration.   
2.4.3. FLUORESCENCE MICROSCOPY 
 
 As mentioned above, imaging of cells on scaffolds was carried out to ensure that cells 
were successfully attached and had infiltrated the scaffolds.  In order to do this, the cells were 
first fixed by placing methanol in the wells for ten minutes.  The scaffolds were allowed to air 
dry and then placed at -80 °C.  Scaffolds were permeabilized in 0.1% Triton X-100 (Shelton 
Scientific, Inc., Shelton, CT) in PBS at ambient temperature.  0.1% Triton X-100 is an organic 
solvent that, in this particular application, was used to coagulate proteins and used to fix and 
permeabilize cells [41].  Scaffolds were then washed with PBS three times for five minutes.  
Permeabilization was done in order to allow 4’,6-diamidino-2-phenylindole (DAPI) to enter the 
cell and stain the DNA, using DAPI in PBS (1 μg/ml) for 30 minutes in the dark.  After DAPI 
staining, the scaffolds were again washed with PBS three times for five minutes and stored in the 
dark until they were cryosectioned.  When the scaffolds were ready to be cryosectioned, they 
were embedded in Neg50 frozen section medium (Thermo Fisher, Asheville, NC), cryosectioned 
at 10 μm and immediately mounted onto glass slides.  The sectioned samples were then mounted 
with Vectashield Mounting Medium For Fluorescence (Vector Laboratories Inc., Burlingame, 
CA) and examined using a Zeiss Axiovert 200M fluorescence microscope (Carl Zeiss 
Microimaging, Inc, Thornwood, NY) [6]. 
     
2.4.4. LIVE/DEAD ANALYSIS    
 
After cells had been cultured for 7 days on the small and medium fiber diameter 
scaffolds, they were then treated with cisplatin for 72 hours.  A live/dead analysis was performed 
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in order to determine the survival rate of cancer cells after being treated with a chemotherapeutic 
drug in 3D.  The scaffolds were initially washed with PBS and then were placed in the assay that 
correlated with either viable cells or dead cells.  The scaffolds were stained with 10 µM 5-
chloromethylfluorescein diacetate (CMFDA) to stain live cells and 5 µM of ethidium 
homodimer-1 (EthD-1) for dead cells.  The disks were incubated for 40 minutes, and then 
washed with PBS for five minutes three times.  The disks were then fixed in 4% PFA, stained 
with DAPI, cryosectioned, and imaged as described above.  Viability was calculated by counting 
the percentage of live cells per field of view from five randomly chosen fields of view from three 
samples per condition [6]. 
Chapter 3 
Results and Discussions 
3.1. Monolayer Cell Toxicity Tests 
3.1.1. PACLITAXEL TREATMENT 
A monolayer of each cell line was cultured directly on 96-well culture plates.  Increasing 
amounts were tested in triplicate from no drug to paclitaxel concentrations that elicited ~100% 
cell death (0% survival).  After 72 hours of paclitaxel treatment, the WST-1 assay was used as a 
colorimetric assay to quantify cell viability.  In this assay, viable cells are able to create 
formazan-dyes, the absorbance of which can be read in a 96-well plate reader.  Absorbance was 
measured at 450 nm and 650 nm wavelengths, and a blank well was read simultaneously in order 
to subtract background noise in the absorbance calculations.  Averages of the absorbances from 
the non-treated samples represented 100% cell viability.  All other drug concentrations were 
compared to this in order to determine the IC90 concentration. 
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Figure 3.1 shows the percentage of HN6 cells that survive following treatment with 
paclitaxel.  The IC90 calculation confirmed that 45 nM was the effective concentration needed to 
kill 90% of the cell population.  The corresponding concentrations of paclitaxel tested on the 
monolayer of HN6 cells can be found in Table 3.1.  These values show exact survival 
percentages of HN6 cells at each drug concentration and validate the IC90 calculation. 
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Table 3.1: Paclitaxel concentrations (nM) used during monolayer HN6 cell drug toxicity 
testing. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: HN6 cells are sensitive to paclitaxel in 2D culture. HN6 cells were grown in 2D 
culture, then incubated with the indicated doses of paclitaxel for 72 hours. A formazan dye 
viability assay was performed to construct the dose response curve and 45nM paclitaxel 
was determined to be the IC90 (n=15). 
 
 
 
  
 
Paclitaxel Concentration (nM) 0 5 10 20 40 60 100 
HN6 Cell Survival (%) 100 45 33 23 13 6 4 
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HN12 cell culture and paclitaxel treatment were identical to the drug toxicity tests 
performed on HN6 cells.  To keep a consistent comparison between the two cell lines, the same 
concentrations for paclitaxel were tested on the monolayer of HN12 cells.  The IC90 calculations 
from these tests indicated that 98 nM paclitaxel was needed to kill 90% of the cell population 
(Figure 3.2). Table 3.2 displays the concentrations used during drug testing and the 
corresponding cell survival percentages.   
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Table 3.2: Paclitaxel concentrations (nM) used during monolayer HN12 cell drug toxicity 
testing. 
 
 
 
 
Figure 3.2: HN12 cells are sensitive to paclitaxel in 2D culture. HN12 cells were grown in 
2D culture, then incubated with the indicated doses of paclitaxel for 72 hours. A formazan 
dye viability assay was performed to construct the dose response curve and 98nM Taxol 
was determined to be the IC90 (n=15). 
 
 
 
Paclitaxel Concentration (nM) 0 5 10 20 40 60 100 
HN12 Cell Survival (%) 100 43 35 28 20 17 8 
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3.1.2. CISPLATIN TREATMENT 
 HN12 and HN6 cells were cultured as monolayers as previously described, and were then 
treated with increasing amounts of cisplatin for 72 hours.  All absorbance readings from the 
WST-1 assay were analyzed as outlined above, resulting in decreasing cell survival with 
increasing concentrations of cisplatin.   
HN 6 monolayer cells were found to be very sensitive to cisplatin.  Cisplatin was potent 
at low concentrations, and as the drug concentration increased, 100% of cells were killed (Figure 
3.3).  The calculated IC90 for cisplatin in HN6 monolayer drug testing was 6µg/ml.  Increasing 
concentrations resulted in 0% of the HN6 cells remaining viable (Table 3.3).   
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Table 3.3: Cisplatin concentrations (µg/ml) used during monolayer HN6 cell drug toxicity 
testing. 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 3.3: HN6 cells are sensitive to cisplatin in 2D culture. HN6 cells were grown in 2D 
culture, then incubated with the indicated doses of cisplatin for 72 hours. A formazan dye 
viability assay was performed to construct the dose response curve and 6 µg/ml cisplatin 
was determined to be the IC90 (n=21). 
 
 
 
Cisplatin Concentration (µg/ml ) 0 2.5 4 5 6 8 10 20 40 50 
HN6 Cell Survival (%) 100 53 39 18 11 4 2 0 2 0 
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HN12 cells were treated identically to HN6 cells with the same concentrations of 
cisplatin.  The data remained consistent with those for HN6 cells cultured in monolayers in that 
HN12 cells were sensitive to cisplatin (Figure 3.4).  An IC90 of 5µg/ml was determined for HN12 
cells in monolayer, which was close to the IC90 value of HN6 treated with cisplatin.  Table 3.4 
shows HN12 cell survival with each cisplatin drug concentration.  
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Table 3.4: Cisplatin concentrations (µg/ml) used during monolayer HN12 cell drug toxicity 
testing. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: HN12 cells are sensitive to cisplatin in 2D culture. HN12 cells were grown in 2D 
culture, then incubated with the indicated doses of cisplatin for 72 hours. A formazan dye 
viability assay was performed to construct the dose response curve and 5 µg/ml cisplatin 
was determined to be the IC90 (n=36). 
 
 
 
 
 
Cisplatin Concentration (µg/ml ) 0 2.5 4 5 6 8 10 20 40 50 
HN12 Cell Survival (%) 100 65 22 18 1 0 0 0 2 0 
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3.1.3. IC90 CALCULATIONS AND RESULTS 
 A statistical tool (GraphPad Prism) was used in order to calculate the IC90 value for each 
cell type and its corresponding drug treatment.  Absorbance data, including averages of all 
survival percentages, standard deviations, and number of samples were extracted from Microsoft 
Excel and translated to GraphPad Prism where a drug dose response analysis was performed.  
The software was able to compute values needed for IC90 calculations such as IC50 and Hill slope 
(H).  These values were then used in IC90 calculation (Equation 1) [39].   
          ((
 
 
)       ( ))   Equation 1 
Table 3.5: Overview of calculated IC90 for both HN6 and HN12 treated with either 
paclitaxel or cisplatin. 
 HN6 HN12 
Paclitaxel (nM) 45 98 
Cisplatin (µg/ml) 6 5 
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3.2. Monolayer Cell Toxicity Tests: Conclusions  
It was found that both cell types, HN6 and HN12, were sensitive to both paclitaxel and 
cisplatin.  Compared to previous in vitro doses of 40nM, there was less sensitivity to paclitaxel 
[6].  While comparing the differences in drug dose responses between HN6 and HN12 cells in 
monolayers, HN6 cells were found to be more sensitive to paclitaxel.  Therefore, a lower 
concentration of paclitaxel was needed to kill HN6 cells than HN12 cells.  HN12 cells may be 
more resistant to paclitaxel because of their higher doubling time compared to HN6.  Although, 
exact doubling times were not calculated in these experiments, HN12 cells in 2D culture were 
shown to proliferate at a faster rate than HN6 cells.  Paclitaxel works by targeting the cell cycle 
and arresting the cells in mitosis.  It could be possible that at the time of treatment not all of the 
HN12 cells were in the M stage of the cell cycle due to its rapid cell cycle.  It has been found that 
cell death is markedly reduced in cells blocked at the G1-S transition phase [40].   
As discussed earlier, both HN6 and HN12 were notably sensitive to similar small dosages of 
cisplatin.  Cisplatin has an anti-tumor effect by directly binding to DNA, causing platinum DNA 
monoadducts.  These adducts can then inhibit cell proliferation, and if the DNA is not repaired, 
cell death can occur [43].  Since cisplatin does not target a stage of the cell cycle, but rather a 
vital structure of the cancer cells, this could explain the high sensitivity experienced by both 
HN6 and HN12 cells.  There is also a possibility that HN6 and HN12 have a higher level of 
microtubule resistant mechanisms, which would reduce the effects of mitotic arrest caused by 
paclitaxel.   These cell lines might also have a lower level of platinum to DNA binding resistant 
mechanisms which would enhance the effects of cisplatin.  Clinical doses of cisplatin effectively 
and consistently killed both HN6 and HN12 monolayer cell lines, therefore it was decided that a 
concentration of 6 μg/ml of cisplatin would be used for future drug testing in 3D models. 
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3.3. Scaffold Fabrication 
3.3.1. QUANTIFYING SMALL, MEDIUM, AND LARGE FIBER DIAMETER 
SCAFFOLDS 
 Differences in fiber dimensions were investigated in order to understand how fiber 
diameter affects the growth of cells and drug efficacy in a 3D in vitro cancer model.  As 
explained previously, engineered scaffolds represent the microenvironment of a tissue.  Scaffolds 
are engineered ECM designed to support host cells and elicit an environment where host cells 
can regenerate tissue.  Tissue engineering provides the possibility to manipulate several different 
parameters within the engineered ECM.  Altering parameters in the engineered scaffold will 
result in different cellular functions.   
 In this study, the ECM parameter of interest to investigate was fiber diameter size: small, 
medium, and large, which were directly related to nanofiber sizes produced during 
electrospinning of PLLA.  The concentration of PLLA polymer solution in HFP was directly 
related to the size of fibers produced.  It was found that 55 mg/ml was the lowest polymer 
concentration that electrospun the smallest fiber diameters without causing any beading of the 
polymer.  It is often found that electrospun fibers will have beads as “by products” which is 
related to the instability of the jet polymer, or that the polymer concentration is too low [41].  
The polymer concentration of PLLA required to produce the largest size fibers was 180 mg/ml.  
A concentration of 115 mg/ml produced fibers of medium diameter, which was a midpoint 
between the small and large concentrations. These three fiber sized scaffolds were quantified and 
characterized prior to introducing any cell lines. 
 In order to quantify the three different fiber sizes, the scaffolds were imaged by SEM and 
the fiber diameters were measured with NIH ImageJ.  Three scaffolds were made for each fiber 
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size, and three samples were taken from each scaffold.  Therefore, nine randomly selected 
images of each scaffold size were produced. 100 fiber width measurements in total were made 
for each scaffold size using the length-measuring tool in NIH ImageJ.  Figure 3.5 shows 
comparative SEM images of the three different fiber diameters.  A linear relationship between 
PLLA concentration and fiber diameter is represented in Figure 3.6.  It was found that for small, 
medium, and large the average fiber widths were 0.5 µm, 1.7µm, and 5.1 µm respectively.   
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Figure 3.5: SEM image of (A) small fiber diameters, (B) medium fiber diameters, and (C) 
large fiber diameters constructed by electrospinning polymer solution of 55mg/ml, 
115mg/ml, and 180mg/ml of PLLA into HFP respectively.  The average fiber diameter 
width was 0.5±0.2µm, 1.7±0.3µm, and 5.1±1.2µm for small, medium, and large respectively 
(n=100). 
 
A 
B 
C 
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Figure 3.6: Graphical comparison of average fiber diameters between small, medium, and 
large fiber diameter scaffolds.  Measurements were made using ImageJ (n=100, +/-s.e.m.). 
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3.3.2. UNIAXIAL TENSILE TESTING 
 Collecting mechanical data is a helpful tool to compare different tissue engineered 
scaffolds.  There are several reasons why it is imperative to test scaffolds under mechanical 
stresses, for example the scaffold material may need to undergo harsh stresses and strains in an 
artificial artery.  For this study, mechanical testing was used in order to compare the properties of 
small, medium, and large fibers.  The goal was to explore ideal mechanical properties needed for 
cell seeding and infiltration in cancer models.  
 Uniaxial tensile testing was done using an MTS Bionix testing system with a 100 N load 
cell, as described previously.  For each of the fiber sized scaffolds, width, thickness, peak load, 
peak stress, modulus, strain at break, and energy at break were calculated using TestWorks 
version 4.  Table 3.6, Table 3.7, and Table 3.8 show the mechanical data for small, medium, and 
large fiber scaffolds, respectively.  Three scaffolds were electrospun for each concentration and 
three dog bone shapes were punched out of each scaffold.  Therefore, nine total tensile tests were 
made for each fiber size scaffold.  Graphical comparisons of different mechanical parameters 
between the small, medium, and large fiber scaffolds can be seen in Figure 3.7.   
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Table 3.6: Unaxial tensile testing of PLLA for small fiber diameter scaffolds. (n=9). 
Small        
 Width 
(in.) 
Thickness 
(in.) 
Peak 
Load 
(N) 
Peak 
Stress 
(Mpa) 
Modulus 
(Mpa) 
Strain at 
Break 
(mm/mm) 
Energy 
To Break 
(N*mm) 
Mean 0.105 0.00256 0.631 5.55 59.4 0.265 0.849 
S.D. 1.46E-17 0.00172 0.251 3.36 35.7 0.0581 0.41 
 
Table 3.7: Unaxial tensile testing of PLLA for medium fiber diameter scaffolds. (n=9). 
Medium        
 Width 
(in.) 
Thickness 
(in.) 
Peak 
Load 
(N) 
Peak 
Stress 
(Mpa) 
Modulus 
(Mpa) 
Strain at 
Break 
(mm/mm) 
Energy 
To Break 
(N*mm) 
Mean 0.105 0.00711 1.62 3.36 96.2 0.188 1.84 
S.D. 1.46E-17 0.00129 0.515 0.735 28.2 0.0418 0.864 
 
Table 3.8: Unaxial tensile testing of PLLA for large fiber diameter scaffolds. (n=9). 
Large        
 Width 
(in.) 
Thickness 
(in.) 
Peak 
Load 
(N) 
Peak 
Stress 
(Mpa) 
Modulus 
(Mpa) 
Strain at 
Break 
(mm/mm) 
Energy 
To Break 
(N*mm) 
Mean 0.105 0.0165 1.75 1.57 2.11 2.78 1.52 
S.D. 1.46E-17 0.317 0.317 0.284 0.554 0.345 0.375 
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Figure 3.7: Graphical comparison of (A) average thickness, (B) peak stress, (C) 
strain at break, and (D) modulus between small, medium, and large fiber diameter 
scaffolds.  Measurements were made with hand-held calipers and MTS machine (n=9). 
 
 
B 
D 
C 
A 
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3.3.3. ANALYSIS OF SCAFFOLD PORE SIZES AND POROSITY 
 Porosity and pore size of 3D scaffolds have direct implications for the functionality of the 
scaffold during biomedical applications.  It is essential to have a porous ECM so there are 
interconnected networks of cell nutrition, proliferation, and migration for tissue vascularization.  
High porosity enables the release of bio factors including genes, proteins, cells, and nutrient 
exchange.  A porous scaffold also serves to maintain structural stability of the biomaterial 
through its interconnected networking of fibers [42].   
 SEM Images of the small, medium, and large fiber size scaffolds were assessed using 
NIH ImageJ.  The software was able to transfer the images to black and white, find the edges, 
and calculate the amount of area that represented pores as well as the average pore size.  Three 
scaffolds were electrospun for each fiber size, and three samples were imaged through SEM.  
Nine total images for each fiber size were evaluated for average pore size and porosity.  The 
average pore sizes for small, medium, and large fiber scaffolds were 2.8±0.7 μm2, 6.6±1.2 μm2, 
and 5.7±2.0 μm2 respectively (Figure 3.8 A).  As fiber size increased, there was a relative 
increase in pore size with variability in some of the large fiber scaffolds.  Porosity decreased 
with the increase in fiber diameter.  The porosities of the small, medium, and large fiber 
scaffolds were 53.8±3.3 %, 42.5±1.9 %, and 26.0±2.5 % respectively (Figure 3.8 B).   
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Figure 3.8: Graphical comparison of (A) average area of pores and (B) porosity between 
small, medium, and large fiber diameter scaffolds.  Measurements were made using 
ImageJ.  (n=9,+/- s.e.m.). 
A 
B 
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3.4. Scaffold Fabrication: Conclusions 
Several parameters were examined during scaffold fabrication; the primary design 
parameter that was desired for comparison was different fiber widths.  The goal was to design 
three different scaffolds comprised of all small fibers, all medium fibers, or all large fibers.  
These fiber dimensions were generated by electrospinning different concentrations of PLLA 
polymer.  It was found that there was a linear relationship between PLLA concentration and fiber 
diameter (Figure 3.6).  Optimal concentrations of PLLA were found to be 55 mg/ml, 115 mg/ml 
and 180 mg/ml for generating small, medium, and large diameter fibers, respectively.  In order to 
define these concentrations it was important to determine when the fibers were too unstable, or 
the concentration was too low, versus when the polymer was unable to electrospin because the 
concentration was too high.  Parameters were manipulated to design the small and large fiber 
sizes.  A concentration in the middle range of these two concentrations was then chosen to 
generate medium size fibers.   
 Uniaxial tensile testing was performed on each of the scaffold types in order to compare 
mechanical properties between the three fiber sizes.  There was a positive correlation between 
increase in fiber diameter and thickness of the scaffolds.  It was apparent that the small fiber 
scaffolds were the weakest material considering they were the thinnest and they required the 
least amount of energy to break.  The medium fiber scaffolds were the most elastic material as 
seen by the large modulus and small strain experienced at break.  Both small and medium size 
fiber scaffolds could be defined as brittle structures based on their mechanical data.  The large 
scaffolds showed the highest plastic deformation with a large strain at break value and a small 
modulus.  The large fiber scaffolds took a great amount of energy to break because of the 
thickness and high ductility (Tables 3.6, 3.7, 3.8).   
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Pore size and porosity are two vital parameters to consider while characterizing tissue 
engineered scaffolds.  In this study, it was desired to have cancer cells infiltrate throughout the 
cancer model to most accurately represent a 3D in vivo tumor.  With ideal porosity, cells are able 
to freely move throughout the scaffold.  With interconnected networks the cancer cells would be 
able to diffuse the necessary bio factors (cells or nutrient exchange) to regenerate an appropriate 
tumor model.  It has also been found that porous scaffolds serve to maintain the structural 
stability of the biomaterial [42].  The data show that pore size increased as the fiber diameter 
increased.  Therefore, the small fibers had the smallest pore sizes whereas the medium and large 
fibers had larger pore sizes (Figure 3.8 A).  Larger pore sizes, as well as large fibers, allow for a 
stronger interconnected network therefore explaining why the medium fibers yielded a higher 
modulus and the large fibers took the most energy to break.  
 It is also important to note that there was a negative correlation between fiber size and 
porosity (Figure 3.8 B).  Although the pore sizes did in fact increase with larger fibers, the 
overall percentage of pores per scaffold area decreased.  Higher porosity suggests that smaller 
and medium fiber size scaffolds, average diameters of 500 nm and 1.7 μm respectively, could 
elicit better cell infiltration.  Literature reporting similar nano-scale fiber diameters has 
concluded in successful cell infiltration, although with use of different cells and different 
electropsun polymers [46, 47].  It also could be possible that the thickness of the scaffolds affects 
cell infiltration: the thinner the scaffold, the easier it is for cells to travel through.  When 
compared to previous reports in the literature, it appears that the scaffolds were around 20μm 
thick which was significantly thinner than each of the scaffolds imaged in this study [46].     
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3.5 Analysis of Cell Infiltration in Fabricated Scaffolds 
 In order to design an appropriate in vitro cancer model for testing chemotherapeutic 
drugs, it was essential to ensure that cells are able to seed throughout the scaffold.  The 3D 
model was designed with the intention of testing chemotherapeutic drugs in an environment that 
more closely represented conditions in vivo.  Therefore, it was critical to assess whether or not 
the cells were infiltrating throughout the scaffold.  Cancer cells penetrating the entirety of the 
scaffold would more accurately represent the microenvironment of a 3D tumor.   
 After fabrication, scaffolds were seeded with either HN6 or HN12 cells as described 
previously.  Comparisons were made between cell types, fiber diameters, and length of time in 
cell culture.  Medium and small fiber diameter scaffolds were used to seed cells on and were 
imaged after either seven days or fourteen days to conclude whether or not time was a crucial 
factor.  Images, using fluorescent microscopy, show the scaffolds and cells in phase, stained with 
DAPI, and a merged image of phase with DAPI stained cells.  From these fluorescent images, 
cell infiltration could be examined based on the different parameters.  Experiments for cell 
migration were run in triplicate for each condition, fiber size and culture time.  
HN6 cell infiltration of small fiber diameter scaffolds can be seen in Figure 3.9.  The 
average thickness of the scaffold shown here was 49.0 +/- 2.8 μm (n=10).   Figure 3.10 shows 
the size difference in medium sized fibers, where the average thickness of the scaffold was 83.1 
+/- 4.2 μm (n=10).  HN12 cell infiltration can be seen in Figures 3.11 and 3.12 after day seven 
and day fourteen, respectively, of cell seeding.  The small fiber scaffold in Figure 3.11 showed 
an average thickness of 44.5 +/- 5.5 μm (n=10), whereas the medium fiber scaffold in Figure 
3.12 had an average thickness of 166.8 +/- 23.4 μm (n=10).  Figure 3.13 shows the results from 
HN6 cells seeded on to small fibers after fourteen days with the average scaffold thickness being 
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54.5 +/- 5.0 μm (n=10). Figure 3.14 shows in contrast HN6 cells seeded for fourteen days onto 
medium fiber sizes with a scaffold thickness of 119.6 +/- 9.2 μm (n=10).  HN12 cells were done 
identically to HN6 experiments and Figures 3.15 and 3.16 show HN12 cellular infiltration on 
small fibers and medium fibers respectively.  Average thicknesses of small and medium 
scaffolds were 58.0 +/- 4.2 μm (n=10) and 119.6 +/- 9.2 μm (n=10) respectively.  It is noted that 
for Figures 3.15 and 3.16, HN12 cells were labeled with YFP; therefore four channels were used 
during fluorescent microscopy.   
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3.5.1. DAY 7 CELLULAR INFILTRATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Day 7 HN6 cellular infiltration of small fiber scaffolds.  The average thickness of this 
scaffold is 49.0 +/- 2.8 μm (n=10). 
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Figure 3.10: Day 7 HN6 cellular infiltration of medium fiber scaffolds.  The average 
thickness of this scaffold is 83.1 +/- 4.2 μm (n=10). 
 
 
 
 
 
 
 
 
Phase DAPI 
Phase+DAPI 
 54 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: Day 7 HN12 cellular infiltration of small fiber scaffolds.  The average 
thickness of this scaffold is 44.5 +/- 5.5 μm (n=10). 
 
 
 
 
 
Phase DAPI 
Phase+DAPI 
 55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12: Day 7 HN12 cellular infiltration of medium fiber scaffolds.  The average 
thickness of this scaffold is 166.8 +/- 23.4 μm (n=10). 
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3.5.2. DAY 14 CELLULAR INFILTRATION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13: Day 14 HN6 cellular infiltration of small fiber scaffolds.  The average 
thickness of this scaffold is 54.5 +/- 5.0 μm (n=10). 
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Figure 3.14: Day 14 HN6 cellular infiltration of medium fiber scaffolds.  The average thickness of 
this scaffold is 119.6 +/- 9.2 μm (n=10). 
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Figure 3.15: Day 14 HN12/YFP cellular infiltration of small fiber scaffolds.  The average 
thickness of this scaffold is 58.0 +/- 4.2 μm (n=10). 
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Figure 3.16: Day 14 HN12/YFP cellular infiltration of medium fiber scaffolds.  The average 
thickness of this scaffold is 119.6 +/- 9.2 μm (n=10). 
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3.6. Analysis of Cell Infiltration in Fabricated Scaffolds: Conclusions 
 
HN6 and HN12 cells were seeded onto small and medium fiber size scaffolds for periods of 
seven days and fourteen days in order to analyze cell infiltration.  It was decided to eliminate 
using large fiber scaffolds because the thicker material prevented cryosectioning.  Because of the 
inability to cryosection, large fiber scaffolds were being shredded and inaccurate representations 
of cell infiltration were being imaged.  Therefore, cell seeding was only implemented on small 
and medium fiber scaffolds.   
HN6 cells, after seven days of culturing on small fiber scaffolds (Figure 3.9), showed 
significant infiltration.  The HN6 cells infiltrated throughout the majority of the thickness of the 
scaffold, 49.0+/- 2.8 µm, which could be due to a higher percentage of porosity throughout the 
scaffold.  In contrast, HN6 cells seeded on the medium fiber scaffolds for seven days appeared to 
maintain a monolayer on the surface of the scaffold (Figure 3.10).  The medium fiber scaffolds 
were about double the thickness (83.1 +/- 4.2 µm) of the small fiber scaffolds which could 
inhibit cell infiltration.  As seen in Figure 3.10, the fibers are a larger size than in the smaller 
fiber scaffolds which results in larger pores.  However, this also constitutes for a smaller porosity 
throughout because of the larger area of fibers, which may result in a lack of cell infiltration.   
Figure 3.11 shows HN12 cells cultured for seven days on small fiber scaffolds of comparable 
thickness (44.5 +/- 5.5 µm) to scaffolds used for HN6 cell seeding.  A large portion of the 
scaffold appears to be infiltrated by HN12 cells, although not as noticeable as with HN6 cells.  In 
comparison to medium size fiber scaffolds seeded with HN12 cells for seven days, the scaffold 
was approximately four times thicker than the small scaffold (166.8 +/- 23.4) µm and cells 
infiltrated about halfway through the scaffold.   HN12 cells did appear to infiltrate more 
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efficiently in medium scaffolds than HN6 cells did in medium scaffolds.  However, infiltration 
was still greatest for HN6 cells seeded in small fiber diameter scaffolds.   
HN6 cells cultured for fourteen days on small fiber scaffolds shows cells migrating 
throughout the majority of the scaffold (Figure 3.13).  Although not as uniform as HN6 cell 
infiltration on small fiber scaffolds after seven days, there appears to be areas where cells are 
traveling across the width of the scaffold after fourteen days.  When comparing the small fibers 
to the medium fibers in Figure 3.14, HN6 cells did not infiltrate throughout the scaffold which 
could again be reflective of the increased thickness and decrease in porosity of the medium fiber 
scaffold.  However, there was more infiltration of HN6 cells after fourteen days compared to 
seven days in medium size fiber scaffolds.   
HN12 cells cultured for fourteen days on small fiber scaffolds remained, for the most part, on 
the surface of the scaffold (Figure 3.15).  Figure 3.16 shows that HN12 cells seeded on medium 
fiber scaffolds permitted better infiltration than small fiber scaffolds after fourteen days of 
culture.  This was consistent with data collected after seven days as described previously.   
Overall, time did not appear to play a big factor in cell infiltration when comparing seven 
days to fourteen days.  Seven days of culturing either HN6 or HN12 cell lines onto small fiber or 
medium fiber scaffolds was shown to be a sufficient amount of time for cells to infiltrate.  
Comparing to similar literature that investigated cell infiltration on 3D scaffolds, time points 
were not taken past seven days [46, 47].  Day seven may also be a more ideal duration for cell 
seeding because there is a higher risk of cell death the longer they are maintained in culture.  
Because of this conclusion, treatment of cells with cisplatin was done after seven days of 
culturing for future studies.   
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 Large fiber scaffolds were fabricated and characterized as previously described, yet were 
ultimately not used for cell seeding due to difficulty in cryosectioning.  However, it appears as 
though small and medium fiber scaffolds were more appropriate to use for cell seeding because 
of their smaller thickness and higher porosity.  A smaller scaffold thickness, smaller fiber 
diameters, and a higher percentage in porosity yielded better results for cell infiltration.  HN6 
cells showed higher infiltration in smaller fiber scaffolds whereas HN12 cells showed higher 
infiltration in medium fiber scaffolds.  The fiber diameters for both the small and medium fibers 
elicited sufficient cell infiltration because there was an increase in porosity and a larger size to 
surface area relationship in fibers.  In other words, although the fibers are smaller, there is a 
greater percentage of fiber area present throughout the scaffold [16].  This gives more area for 
the cells to adhere and therefore generates the opportunity for cells to migrate. Small fibers 
seeded with HN6 and medium fibers seeded with HN12 show sufficient cell infiltrations, 
however better infiltration could be achieved with thinner scaffolds.   
 
3.7. Live Dead Analysis of Cisplatin Treated Cells in Fabricated Scaffolds 
3.7.1. LIVE/DEAD ASSAY ON CELLS GROWN IN 2D CULTURE 
In order to quantify the number of viable cells versus dead cells in the engineered 
3D scaffolds a live/dead assay (CMFDA and EthD-1) was used as previously described.  
CMFDA is a fluorescent dye able to freely pass through cell membranes and it is retained in 
living cells to enable future microscopic imaging [43].  This was contrasted with EthD-1, a high 
affinity nucleic acid stain that emits red fluorescence while bound to DNA [44].  Cells were 
seeded onto 2D glass plates as a pilot study to test the efficacy of the assays.  Figure 3.17 shows 
the results of viable cells seeded on a glass plate.  Figure 3.18 shows the result of killing cells 
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with methanol prior to staining with the live dead assay.  Figures 3.17 and 3.18 show the phase 
image, live assay alone, dead assay alone, and a merge of the phase, live and dead assays.  As a 
result of pilot study shown in Figures 3.17 and 3.18, it was concluded that the live/dead assays 
were successfully staining live cells and dead cells respectively, therefore the assays could be 
then transferred to cells grown in 3D scaffolds.   
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Figure 3.17: Live/dead assays tested on cells grown in 2D to test the efficacy of the 
assays on live cells.   
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Figure 3.18: Live/dead assays tested on cells grown in 2D to test the efficacy of the assays 
on dead cells. 
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3.7.2. DAY 10 WITH NO CISPLATIN TREATMENT  
 After investigating the infiltration capabilities of HN6 and HN12 in both small and 
medium fiber scaffolds, it was important to test the viability of these cells in 3D in response to 
chemotherapeutic drugs.  Live/dead assays, as described above, were used to quantify the 
number of viable cells versus the number of dead cells in both fiber size scaffolds after three 
days of 6 μg/ml cisplatin treatments, which was the IC90 determined in 2D culture.  Through the 
live/dead assays the live cells were stained green and the dead cells were stained red and 
analyzed under fluorescence microscopy.  Five random fields were chosen for each cell type 
seeded on both fiber sizes and from these images, percentages of live cells were calculated.  To 
determine whether cell lines seeded onto the scaffolds were affected by cisplatin, treated samples 
were compared to controls with identical cell seeding and no cisplatin treatment.  Figure 3.19 
shows a live/dead analysis of HN6 cells seeded onto small fiber scaffolds after ten days with no 
cisplatin treatment displaying 53.6% of viable cells.  HN6 cells seeded for ten days onto medium 
fiber scaffolds with no cisplatin treatment were imaged as seen in Figure 3.20 and showed 39.2% 
of the overall cell populations was viable.  Figure 3.21 shows HN12 cells seeded for ten days 
onto small fiber scaffolds with no cisplatin treatment, where 71.0% cell viability was counted.  
HN12 cells seeded for ten days on medium fibers with no cisplatin treatment, as seen in Figure 
3.22 showed 58.2% of viable cells (Table 3.9).    
Table 3.9 Cell viability for untreated scaffolds. (n=5).  
 HN12  HN6 
Small Fiber Scaffolds 71.0% 53.6% 
Medium Fiber Scaffolds 58.2% 39.2% 
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Figure 3.19: Day 10 live/dead analysis of HN6 cells seeded onto small fiber scaffolds with no 
cisplatin treatment. Cell viability was calculated to be 53.6% (n=5). 
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Figure 3.20: Day 10 live/dead analysis of HN6 cells seeded onto medium fiber scaffolds with 
no cisplatin treatment.  Cell viability was calculated to be 39.2% (n=5). 
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Figure 3.21: Day 10 live/dead analysis of HN12 cells seeded onto small fiber scaffolds with 
no cisplatin treatment.  Cell viability was calculated to be 71% (n=5).   
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Figure 3.22: Day 10 live/dead analysis of HN12 cells seeded onto medium fiber scaffolds 
with no cisplatin treatment.  Cell viability was calculated to be 58.2% (n=5). 
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3.7.3. DAY 10 AFTER CISPLATIN TREATMENT 
 Fabricated scaffolds were seeded with either HN6 or HN12 cells, and after seven days of 
cell infiltration, were then treated with 6 μg/ml cisplatin.  After 72 hours of cisplatin treatment, 
the live/dead assays were used, as previously described, to quantify the number of viable cells 
versus the number of dead cells.  The live/dead assay was used in comparison with the control 
scaffolds (cells seeded onto scaffolds without cisplatin treatment) in order to quantify the 
efficacy of the 3D in vitro chemotherapeutic drug testing apparatus.  Therefore, in order to 
calculate the number of cells merely affected by cisplatin, the untreated scaffolds were treated as 
100% viable in comparison to the treated scaffolds.  Figure 3.23 shows the result of HN6 cells 
seeded onto small fiber scaffolds for seven days followed by three days of cisplatin treatment, 
where 70.0% cell viability was found when compared to 100% viability in untreated scaffolds.  
HN6 cells seeded onto medium fiber scaffolds for seven days followed by three days of cisplatin 
treatment, as seen in Figure 3.24, displayed a cell viability of 15.6%.  Figure 3.25 displays HN12 
cells seeded on small fiber scaffolds for seven days, where 60.3% cell viability was calculated 
after three days of cisplatin treatment.  HN12 cells seeded onto medium fiber scaffolds after 
seven days followed by three days of cisplatin treatment, as seen in Figure 3.26, showed 69.4% 
cell viability (Table 3.10).   
Table 3.10 Cell viability for scaffolds treated with 6µg/ml cisplatin. (n=5). 
 HN12  HN6 
Small Fiber Scaffolds 60.3% 70.0% 
Medium Fiber Scaffolds 69.4% 15.6% 
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Figure 3.23: Day 10 live/dead analysis of HN6 cells seeded onto small fiber scaffolds after 
three days of cisplatin treatment.  Cell viability was calculated to be 70.0% (n=5). 
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Figure 3.24: Day 10 live/dead analysis of HN6 cells seeded onto medium fiber scaffolds 
after three days of cisplatin treatment.  Cell viability was calculated to be 15.6% (n=5). 
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Figure 3.25: Day 10 live/dead analysis of HN12 cells seeded onto small fiber scaffolds after 
three days of cisplatin treatment.  Cell viability was calculated to be 60.3% (n=5). 
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Figure 3.26: Day 10 live/dead analysis of HN12 cells seeded onto medium fiber scaffolds 
after three days of cisplatin treatment.  Cell viability was calculated to be 69.4% (n=5). 
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3.8. Live Dead Analysis of Treated Cells in Fabricated Scaffolds Conclusions 
HN6 and HN12 cell lines were seeded onto both small and medium fiber scaffolds for seven 
days and then were tested for cell viability.  Half of the scaffolds were treated with the IC90 
concentration of cisplatin, as determined in 2D culture, for 72 hours while half of the scaffolds 
were re-fed with culture media for 72 hours to compare the efficacy of the drug on the two 
different cell lines seeded onto the two different fiber size scaffolds.  As a result, for each 
condition, cisplatin treatment was effective for killing the total number of viable cells.  However, 
the efficacy of cisplatin treatment varied between different conditions.  Initial cell viability 
percentages were determined for each untreated scaffold.  These initial viability percentages 
were then taken as 100% viability of cells that have not been treated by cisplatin in order to 
calculate cell viability post cisplatin treatment.  The 100% cell viability for untreated scaffolds 
was considered in order to take out all other variables, except for cisplatin treatment, that may 
cause cell death.   
HN6 cells seeded for ten days onto small fiber scaffolds untreated showed 53.6% cell 
viability (Figure 3.19, Table 3.9).  This data suggests that about half of the HN6 seeded on to 
small fiber scaffolds remained viable after ten days without any cisplatin treatment.  Several 
possibilities could account for the 46.4% HN6 cell death on untreated small fiber scaffolds 
including ten days being too long to maintain sufficient cell viability, HN6 cell sensitivity to 
PLLA, or a harsh environment for adequate nutrient exchange in porous 3D scaffolds. When 
comparing viability of HN6 cells on small fiber scaffolds between untreated and those treated 
with cisplatin, 100% to 70.0% respectively, there was a drop in 30% cell viability (Figures 3.19 
and 3.23, Tables 3.9 and 3.10).  This confirmed that cisplatin was effective in killing 30% HN6 
cells on small fiber scaffolds when compared to untreated samples.  However, it is apparent that 
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6 μg/ml cisplatin was unable to kill 90% of HN6 cells in the small fiber scaffold as it was shown 
to only kill 30%.  These data confirm reports in the literature suggesting cancer cells show 
resistance to chemotherapeutic drugs when seeded in a 3D microenvironment versus a 2D 
microenvironment.  HN6 cells seeded onto small fiber 3D scaffolds showed a resistance to the 
IC90 value of cisplatin used to kill HN6 cells in 2D (Figures 3.20 and 3.3).  Comparing the two 
conditions, 6 μg/ml of cisplatin killed 89% of HN6 cells seeded on 2D tissue culture plates and 
30% of HN6 cells seeded onto small fiber scaffolds.  Overall, there was a 59% increase in viable 
HN6 cells in small fiber scaffolds than from HN6 cells in 2D culture.  As seen previously in 
Figures 3.9 and 3.13, HN6 cells infiltrated most efficiently in small fiber scaffolds, which may 
accurately mimic an in vivo tumor.  These data suggest that the 3D arrangement of HN6 cells 
could enhance cell survival where HN6 cells become more resistant to the IC90 dose of cisplatin 
successful for killing HN6 cells treated in 2D.   
HN6 cells seeded onto medium fiber scaffolds for ten days with no cisplatin treatment 
showed 39.2% viability (Figure 3.20, Table 3.9).  Similar possibilities, as listed previously, could 
have played a role in killing 60.8% of HN6 cells on medium fibers including harsh cell culture 
environments and ten days being too long for adequate cell viability.  When comparing untreated 
HN6 cells on small fibers to untreated HN6 on medium fibers there is a decrease of 14.4% cell 
viability.  During infiltration studies, it was found that HN6 cells tended to form a monolayer on 
top of medium fiber scaffolds (Figures 3.10 and 3.14).  This lack of HN6 cell infiltration in 
medium fiber scaffolds could account for less cell adhesion and, therefore, an increase in cells 
dying off or being suctioned off while replacing media.  Medium fiber scaffolds seeded with 
HN6 cells that were treated with 6 μg/ml of cisplatin showed 15.6% viability (Figure 3.24, Table 
3.10).  When comparing medium fiber scaffolds seeded with HN6 cells, treated with cisplatin 
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versus untreated, there was a decrease in viability by 84.4%.  A dose of 6 μg/ml was effective in 
killing 85% of HN6 cells in medium fiber scaffolds which disagrees with the assumption that 
cancer cells become resistant to chemotherapeutics in 3D culture.  Comparing HN6 in 2D to 
HN6 cells on 3D medium fiber scaffolds shows similar results, 9% viability and 15% viability 
respectively (Figures 3.3 and 3.24, Table 3.10).  These data suggests that seeding HN6 cells onto 
medium fibers treated with cisplatin will reproduce similar cytotoxicity results to HN6 cells 
treated with cisplatin in 2D.  Because of cell infiltration previously found, Figures 3.10 and 3.14, 
it is possible that HN6 cells seeded onto medium fibers represent an identical monolayer of cells, 
like those seeded in 2D, and is does not accurately represent a 3D tumor model.   
Untreated HN12 cells seeded on small fibers for ten days resulted in the highest initial 
viability of 71% (Figure 3.21).  As previously stated, 29% of HN12 cells seeded on small fibers 
could have died after ten days because of several possibilities such as culture time or 
overpopulation of cells.  Comparing initial viability of HN12 to HN6 cells in untreated scaffolds, 
HN12 cells were more viable on small fibers.  This could be due to HN12 cells being more 
tumorigenic and invasive, and less sensitive to fabricated microenvironments.  Small fiber 
scaffolds seeded with HN12 cells that were treated with cisplatin showed 60.3% viability (Figure 
3.25, Table 3.10).  There was a decrease in viability by 39.7% because of the presence of 
cisplatin.  Table 3.10 shows that 6 μg/ml of cisplatin is effective in killing 39.7% of HN12 cells 
seeded in small fibers rather than the 99% of HN12 cells killed when seeded in 2D as seen in 
Table 3.4.  These data suggest that there is a resistance to cisplatin when transitioning HN12 
from 2D to 3D microenvironments.  Figure 3.11 shows a fair amount of cell infiltration inferring 
a 3D arrangement of HN12 cells in small fibers which could result in a resistance to cisplatin 
treatment.   
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Figure 3.22 shows a viability of 58.2% of untreated HN12 cells seeded onto medium 
fibers after ten days (Table 3.9).  This viability is lower when compared to HN12 cells seeded 
onto small fibers, as previously described, which could be a result of cells being introduced to a 
harsher environment.  According to Table 3.9 it can be concluded, that for both HN12 and HN6, 
cells are less viable in medium fiber size scaffolds.  HN12 cell viability decreased by 12.8%, 
whereas HN6 cell viability decreased by 14.4% when transitioning from seeding on small fibers 
to medium fibers.  Both cell lines may prefer the smaller diameter because there is more surface 
area for adhesion, a higher porosity percentage for nutrient exchange, and more binding sites for 
growth factors which would all enhance the viability of cells.   
Figure 3.16 displays treated HN12 cells on medium fibers to be 69.4% viable, which was 
similar to treated HN12 cells on small fibers (Tables 3.9, 3.10).  Cisplatin was effective in killing 
30.6% of HN12 cells in medium fibers rather than 99% of HN12 cells killed when seeded in 2D, 
as seen in Table 3.4.  These data suggest that there is a resistance to cisplatin when transitioning 
HN12 from 2D to 3D microenvironments.  Figures 3.12 and 3.16 display a fair amount of HN12 
cell infiltration in medium fibers suggesting a 3D arrangement that might increase resistance to 
cisplatin treatment.    
It has been concluded that HN12 show a greater resistance to IC90 values of cisplatin 
than HN6.  It was also shown that HN12 cells were able to infiltrate throughout both scaffold 
types, whereas HN6 cells were only able to infiltrate through the small fibers (however, they 
formed a monolayer on top of the medium fiber scaffolds).  Primary HN12 tumor cells are 
epithelial, yet, through previous work in the lab it has been shown that HN12 cells undergo an 
epithelial to mesenchymal transition during tumorigenesis [6].  This process can occur during 
cancer progression, where epithelial cells 1) lose their junctions and apical-basal polarity; 2) 
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reorganize their cytoskeleton; and 3) undergo a change in the signaling programs that define cell 
shape and reprogram gene expression.  All of these processes increase the motility of individual 
HN12 cells and produces a more invasive phenotype.  Specifically, epithelial actin architecture 
reorganizes, and cells acquire motility and invasive capacities by forming lamellipodia, 
filopodia, and invadopodia- which allow for the progression of cancer cells, and enhance cell 
resistance to apoptosis.   Finding that HN12 cells undergo endothelial to mesenchymal transition 
during tumorogenisis- and therefore have greater mobility- is consistent with the conclusion that 
HN12 cells appeared more invasive, and were able to infiltrate better throughout both scaffolds 
[50]. 
Electrospun scaffolds allow for a porous environment to promote cell infiltration; 
however, upon the introduction of media, wetting the scaffolds can cause contraction and 
densification throughout.  Previous studies have shown that this densification should not affect 
cellular penetration and migration into the scaffolds, although it can reduce permeability.  This 
reduction in permeability throughout the scaffolds can result in decreased nutrient and waste 
diffusion.  Lack of proper diffusion can account for cancer cell death in PLLA scaffolds despite 
the absence of anticancer drugs because of a lack of nutrients and a higher incidence of hypoxia 
induced apoptosis [49].    
Although it was shown through experimentation, it is apparent that cell adhesion 
decreased as fiber diameter increased.  This, as explained previously, is due in part to a more 
localized area provided for cell adhesion, and a closer network of cell-cell interaction which 
promotes cell growth.  The small and medium sized fibers better resembled the micro-
environment of HN12 cells in-vivo- which would allude to small and medium fibers providing 
better cell attachment for HN12 and HN6 in tissue engineered scaffolds.  HN6 cells in particular 
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were trending towards greater cell death as fiber size increased, so it could be inferred that larger 
fibers would be a less desirable micro-environment for HN6 cell viability.   Although not 
included in this study’s results, fluorescent images of large fibers seeded with both HN6 and 
HN12 were taken only to show that very little cell attachment had occurred.   
 
Chapter 4 Future Work 
 
Several different parameters were investigated while designing an ideal 3D scaffold used 
for testing in vitro chemotherapeutic drug efficacy.  As previously described, it was found that a 
smaller fiber size gave opportunity for a higher surface area of fibers and porosity and increased 
cell infiltration.  Therefore, scaffolds characterized as small and medium fiber scaffolds were 
successfully used for seeding of both HN6 and HN12 cells.  For future studies of drug efficacy in 
these cell lines with PLLA engineered scaffolds, HN6 should be seeded onto smaller fiber 
scaffolds whereas HN12 cells should be seeded onto small or medium size scaffolds, as 
previously shown.  No significant difference was found between cell infiltration in seven days 
and fourteen days; therefore, for future work, cells should be cultured for only seven days.  A 
decrease in cell culture duration in 3D scaffolds will minimize possible cell death and increase 
accuracy of drug testing.  It might be important to see if a shorter time point could be used that 
shows similar infiltration, such as four days, that would elicit similar cell infiltration.  Future 
engineered scaffolds should be designed to be thinner in order to ensure 100 percent cell 
infiltration and best represent 3D in vivo HNSCC tumors.  Figures 3.9, 3.12, 3.13, and 3.16 all 
appear to have fair cell infiltration throughout the scaffold ranging from about 25% to about 90% 
of the scaffold thickness.  In order to ensure both HN6 and HN12 cells infiltrate throughout the 
entire scaffold, a smaller volume of PLLA solution in HFP could be electrospun.  For the 
fabrication of each scaffold in these studies, 1 ml of solutions was electrospun, whereas in the 
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future a reduced volume such as 0.75 ml may allow fabrication of thinner scaffolds that permit 
higher cell infiltration.  According to our results, future fabricated scaffolds designed to have 
thicknesses of about 40 μm could induce ideal cell infiltration for HN6 cells seeded on small 
fibers and HN12 cells seeded on small and medium fibers.  
Four different conditions were investigated while designing and implementing an in vitro 
3D cancer model for chemotherapeutic drug testing including HN6 cells seeded on small or 
medium fibers, and HN12 cells seeded on small or medium fibers.  As the results have shown, it 
is apparent that HN6 cells are not as viable as HN12 cells in fabricated scaffolds.  Therefore, it 
may be more beneficial to consider more invasive cell lines that are similar to HN12.  If HN6 
cells are to be used in the future, consider seeding them on smaller fibers as they have proved to 
show better infiltration and viability.  It also may be more beneficial for HN12 cells to just be 
seeded onto small fiber scaffolds, as the data have shown that both cell lines are less viable in 
medium fiber scaffolds (Table 3.9).  Each of these conditions was treated with 6 μg/ml of 
cisplatin, which was found to be an accurate IC90 concentration for both cell lines seeded in 2D.  
The results of these treated scaffolds were then compared to each other as well as to untreated 
control scaffolds seeded for the same duration of ten days.  For overall cisplatin treatment 
testing, the number of days for cell seeding could be reduced.  It is possible that this is the main 
cause for untreated cells not being closer to 100% viable.  As recommended previously, seeding 
for 4 days may allow enough time for cells to infiltrate and minimize amount of cell death.  After 
day 4, the cells could then be treated with cisplatin for 72 hours, totaling 7 days of cell seeding 
rather than 10 days.  It might also be important to look into blending natural ECM components 
into the scaffolds to increase cell adhesion.  Another consideration is to introduce air flow during 
electrospinning to fabricate more porous scaffolds, if a lack of nutrient exchange is a concern.  
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Increasing treatments of cisplatin could then be administered to each condition, much like those 
seen in Tables 3.3 and 3.4.  From there it would then be possible to identify an IC90 concentration 
for cisplatin in 3D and compare that value to the IC90 concentrations found in 2D cell seeding.  
The IC90 concentration found while testing cisplatin on HN6 and HN12 in 3D culture 
environments could then be compared to clinical doses of cisplatin to determine the efficacy of 
the in vitro engineered 3D cancer model.   
Drug permeability through the scaffold was not specifically measured. Future studies will 
need to be done in order to determine the exact permeability; however, based on the images 
produced by the live/dead assay and the scaffolds’ porosity, several inferences can be drawn.  
First, as shown in Figures 3.23-3.26, when the live/dead assays were conducted on the cancer-
seeded scaffolds treated with cisplatin, cell death can be observed throughout the scaffolds. 
While such an analysis is by no means conclusive, it does at least suggest that the drugs were 
able to spread throughout the two types of scaffolds. Moving forward, more studies will need to 
be done to determine the exact permeability of cisplatin in PLLA scaffolds with identical 
scaffold parameters.  
It has been concluded that both cancer cell lines develop a resistance to cisplatin when 
seeded in a 3D culture.  Although, it became apparent that cisplatin was successful in killing a 
percentage of cells in each fiber size scaffolds; though a quantitative measurement of how 
effectively the drug was permeating through the scaffold is undetermined.  For future studies it 
would be important to conduct experiments similar to Sell et al. in order to calculate the 
permeability of the drug inside both the small fiber and the medium fiber scaffolds [49].  
Identical scaffolds could be designed with the same thickness, porosity, and fiber diameter to test 
how much of the drug concentration can travel throughout the scaffold.  A flowmeter could be 
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used that allows a specific amount of fluid to pass through a fixed electrospun scaffold over time.  
By using a similar method as Sell et al., a known amount of liquid can be poured into a filling 
port where it is then pushed though through a glass tubing where the electrospun is encased.  The 
scaffolds would be punched into the same diameter shapes used for cell seeding and would be 
vacuumed inside the flow meter to eliminate any other external variables.  These scaffolds could 
then be tightly compressed in the apparatus to ensure that the liquid will perfuse through a 
specific area of the scaffold.  The perfused liquid would flow through the scaffold past a metal 
screen and into a beaker.  Calculations could then be made in order to compare the amount of 
starting fluid to the amount of resulting perfused fluid.  Prior experiments have tested the 
flowmeter by perfusing water through the scaffolds, but in order to test cisplatin permeability it 
would be useful to perfuse the scaffolds with a liquid of identical viscosity- or even the cisplatin 
solution itself.  A dye, such as food coloring, could then be added to the solution in order to 
visualize where perfusion occurs within the scaffolds.  After gathering these data, it could then 
be compared to the porosity calculations and the live/dead analyses previously determined in 
order to conclude the extent to which cisplatin perfuses through electrospun PLLA scaffolds of 
small and medium fiber types.     
Future scaffolds could be electrospun with PLLA in combination with other natural 
polymers.  3D matrices formed with the combination of polymer and natural polymer (ie. 
laminin, collagen, gelatin) have an advantage because biological sources derived from the ECM 
provide mechanical cues that affect cell behavior, gene expression, and drug sensitivity.  The 
inclusion of ECM molecules can initiate signal cascades in tumor cells and function as bio-active 
molecules, such as ligands.  These ligands can be sued for a number of cell surface receptors and 
integrins which could activate downstream target proteins that can activate various signaling 
 85 
 
pathways in cancer cells such as angiogenesis, cancer cell motility, and drug sensitivity.  For 
example, Collagen I can interact with integrins and affect gene expression; which in turn allows 
for the production of enzymes that degrade ECM components allowing for cancer invasion, cell 
sensitivity to cancer drugs, cell proliferations, and migration.  In short, the inclusion of a natural 
polymer blend in the PLLA electrospun scaffolds could better mimic in-vivo ECM of HN12 and 
HN6 cells.  This more natural ECM may allow the cells to better mimic their response to 
cisplatin in vivo and represent appropriate drug sensitivity experienced in the body [22]. 
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Figure 3.6 Fiber Widths 
One Way Analysis of Variance 
Raw Data: 
Small (55 mg/ml) Medium (115 mg/ml) Large (180 
mg/ml) 
0.468 1.600 5.906 
0.317 1.769 5.637 
0.516 1.684 5.780 
0.726 1.765 4.368 
0.326 1.915 6.039 
0.392 1.766 5.515 
0.277 1.698 4.915 
0.620 1.817 5.670 
0.435 1.882 5.639 
0.709 1.698 5.586 
0.392 1.770 5.657 
0.601 1.876 5.997 
0.496 1.897 5.997 
0.653 2.012 4.648 
0.365 1.746 4.910 
0.532 1.156 4.331 
0.404 1.765   
0.594 1.471 6.395 
0.675 1.475 6.067 
0.351 1.593 6.981 
0.577 2.095 6.119 
0.387 1.897   
0.439 1.860 2.725 
0.387 1.832 8.216 
0.369 2.085 4.678 
0.351 1.648 6.468 
0.346 1.710 4.693 
0.697 1.749 4.233 
0.439 1.789 7.341 
0.231 1.886 4.114 
0.238 1.294 6.277 
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0.516 1.824 4.840 
0.408 2.527 7.927 
0.465 1.656 3.014 
0.752 1.786 6.274 
0.416 2.014 1.849 
0.923 2.039 5.195 
0.476 1.746 5.165 
0.588 1.618 5.080 
0.739 1.958 4.346 
0.658 1.749 4.682 
1.168 2.611 4.666 
0.490 1.664 4.134 
0.294 2.584 3.656 
0.516 1.295 4.396 
0.695 1.615 6.534 
0.404 1.648 4.547 
0.547 1.626 5.170 
0.547 1.890 6.242 
0.496 1.250 4.873 
0.588 1.153 4.338 
0.469 1.462 3.887 
0.231 1.438 5.023 
0.430 1.905 5.628 
0.673 1.334 5.615 
0.430 1.350 4.895 
0.586 1.790 5.019 
0.560 1.006 5.392 
0.392 0.925 5.242 
0.463 1.688 4.692 
0.306 1.462   
0.731 1.294 4.507 
0.361 1.472 4.900 
0.350 1.739 4.649 
0.484 1.334 6.915 
0.361 1.463 4.782 
0.478 1.676 5.221 
0.391 1.575 5.109 
0.471 1.336 6.926 
0.316 1.575 5.181 
0.423 1.732 5.631 
0.416 2.000 5.670 
0.409 1.821 5.072 
0.470 1.298 5.713 
0.509 1.789 5.637 
0.385 1.036 6.360 
0.587 1.239 4.835 
0.532 1.996 4.942 
0.196 1.736 3.565 
0.611 1.517 6.039 
0.532 1.074 2.278 
0.416 1.745 2.031 
0.438 1.654 7.859 
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0.525 1.520 4.770 
0.637 1.705 6.697 
0.597 1.360 5.386 
0.334 1.206 4.550 
0.316 1.849 5.396 
0.596 1.617 5.179 
0.476 1.705 3.923 
0.471 1.965 4.442 
0.282 1.720 4.638 
0.554 2.113 2.771 
0.385 1.708 4.991 
0.527 1.241 2.735 
0.582 1.947 4.225 
0.238 1.491 5.662 
0.532 1.648 5.830 
0.385 1.390 6.731 
0.473 1.754 4.680 
 
Table Analyzed Data 1 
    
Kruskal-Wallis test   
P value < 0.0001 
Exact or approximate P value? Gaussian Approximation 
P value summary *** 
Do the medians vary signif. (P < 0.05) Yes 
Number of groups 3 
Kruskal-Wallis statistic 262.0 
Number of 
values 
100 100 97 
        
Minimum 0.1960 0.9250 1.849 
25% Percentile 0.3855 1.471 4.594 
Median 0.4705 1.705 5.109 
75% Percentile 0.5808 1.830 5.805 
Maximum 1.168 2.611 8.216 
        
Mean 0.4831 1.669 5.151 
Std. Deviation 0.1517 0.3049 1.181 
Std. Error 0.01517 0.03049 0.1199 
        
Lower 95% CI 0.4530 1.608 4.913 
Upper 95% CI 0.5132 1.729 5.389 
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Figure 3.7 Mechanical Testing of Scaffolds 
One Way Analysis of Variance 
(A) Average Thickness 
Small (55 mg/ml) Medium (115 mg/ml) Large (180mg/ml) 
0.0050 0.0050 0.0165 
0.0045 0.0070 0.0165 
0.0030 0.0065 0.0165 
0.0030 0.0095 0.0165 
0.0025 0.0075 0.0165 
0.0035 0.0085 0.0165 
0.0005 0.0070   
0.0005 0.0065   
0.0005 0.0065   
 
 
  
Table Analyzed Data 1     
        
One-way analysis of variance       
P value < 0.0001     
P value summary ***     
Are means signif. different? (P < 0.05) Yes     
Number of groups 3     
F 199.7     
R squared 0.9501     
        
Bartlett's test for equal variances       
Bartlett's statistic (corrected)       
P value       
P value summary ns     
Do the variances differ signif. (P < 0.05) No     
        
ANOVA Table SS df MS 
Treatment (between columns) 0.0007059 2 0.0003529 
Residual (within columns) 0.00003711 21 0.000001767 
Total 0.000743 23   
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Number of 
values 
9 9 6 
        
Minimum 0.0005 0.0050 0.0165 
25% Percentile 0.0005 0.0065 0.0165 
Median 0.0030 0.0070 0.0165 
75% Percentile 0.0040 0.0080 0.0165 
Maximum 0.0050 0.0095 0.0165 
        
Mean 0.002556 0.007111 0.0165 
Std. Deviation 0.001722 0.001294 0.0 
Std. Error 0.0005740 0.0004312 0.0 
        
Lower 95% CI 0.001232 0.006117 0.0165 
Upper 95% CI 0.003879 0.008106 0.0165 
 
(B.) Peak Stress 
Small (55 mg/ml) Medium (115 mg/ml) Large (180 mg/ml) 
2.638 3.714 1.966 
2.536 3.591 1.219 
2.752 3.867 1.641 
3.297 4.521 1.276 
5.646 2.368 1.747 
3.492 2.468 1.562 
9.679 3.621   
10.146 3.512   
9.743 2.546   
 
Table Analyzed Data 1     
        
One-way analysis of variance       
P value 0.0063     
P value summary **     
Are means signif. different? (P < 0.05) Yes     
Number of groups 3     
F 6.511     
R squared 0.3827     
        
Bartlett's test for equal variances       
Bartlett's statistic (corrected) 27.98     
P value < 0.0001     
P value summary ***     
Do the variances differ signif. (P < 0.05) Yes     
        
ANOVA Table SS df MS 
Treatment (between columns) 59.02 2 29.51 
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Residual (within columns) 95.19 21 4.533 
Total 154.2 23   
 
Number of 
values 
9 9 6 
        
Minimum 2.536 2.368 1.219 
25% Percentile 2.695 2.507 1.262 
Median 3.492 3.591 1.602 
75% Percentile 9.711 3.791 1.802 
Maximum 10.15 4.521 1.966 
        
Mean 5.548 3.356 1.569 
Std. Deviation 3.363 0.7346 0.2839 
Std. Error 1.121 0.2449 0.1159 
        
Lower 95% CI 2.963 2.792 1.271 
Upper 95% CI 8.133 3.921 1.866 
 
(C.) Strain At Break 
Small (55 mg/ml) Medium 
(115 
mg/ml) 
Large 
(180mg/ml) 
0.229 0.214 2.952 
0.266 0.184 2.470 
0.190 0.268 3.218 
0.217 0.221 2.541 
0.320 0.171 2.410 
0.274 0.141 3.072 
0.329 0.154   
0.209 0.195   
0.351 0.142   
 
Table Analyzed Data 1 
    
Kruskal-Wallis test   
P value 0.0002 
Exact or approximate P value? Gaussian Approximation 
P value summary *** 
Do the medians vary signif. (P < 0.05) Yes 
Number of groups 3 
Kruskal-Wallis statistic 16.83 
 
Number of 
values 
9 9 6 
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Minimum 0.1900 0.1410 2.410 
25% Percentile 0.2130 0.1480 2.455 
Median 0.2660 0.1840 2.747 
75% Percentile 0.3245 0.2175 3.109 
Maximum 0.3510 0.2680 3.218 
        
Mean 0.2650 0.1878 2.777 
Std. Deviation 0.05805 0.04183 0.3455 
Std. Error 0.01935 0.01394 0.1410 
        
Lower 95% CI 0.2204 0.1556 2.415 
Upper 95% CI 0.3096 0.2199 3.140 
 
Figure 3.8 Pore Size and Porosity 
One Way Analysis of Variance 
(A) Average Area of Pores 
Small (55 mg/ml) Medium (115 mg/ml) Large (180 mg/ml) 
3.105 5.778 6.555 
3.397 5.032 3.683 
  8.725 6.309 
2.254 6.954 9.538 
1.453 5.857 5.673 
2.365 6.429 6.260 
2.697 6.962 3.227 
2.569 4.971 4.363 
3.266 7.315 6.614 
3.727 7.574 8.195 
2.672     
 
Table Analyzed Data 1     
        
One-way analysis of variance       
P value < 0.0001     
P value summary ***     
Are means signif. different? (P < 0.05) Yes     
Number of groups 3     
F 22.83     
R squared 0.6284     
        
Bartlett's test for equal variances       
Bartlett's statistic (corrected) 9.030     
P value 0.0109     
P value summary *     
Do the variances differ signif. (P < 0.05) Yes     
        
ANOVA Table SS df MS 
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Treatment (between columns) 85.37 2 42.68 
Residual (within columns) 50.48 27 1.870 
Total 135.8 29   
 
10 10 10 
      
1.453 4.971 3.227 
2.337 5.592 4.193 
2.685 6.692 6.285 
3.299 7.380 7.009 
3.727 8.725 9.538 
      
2.751 6.560 6.042 
0.6569 1.183 1.944 
0.2077 0.3739 0.6147 
      
2.281 5.714 4.651 
3.220 7.406 7.432 
 
(B) Porosity  
Small (55 mg/ml) Medium (115 mg/ml) Large (180mg/ml) 
52.5 44.2 24.0 
53.9 41.3 23.8 
  44.7 27.8 
57.3 39.3 27.6 
49.3 41.9 28.3 
56.0 41.8 28.3 
52.7 41.7 21.6 
57.5 42.2 26.5 
58.4 42.3 33.0 
50.5 46.0 27.8 
50.0     
 
Table Analyzed Data 1 
    
Kruskal-Wallis test   
P value < 0.0001 
Exact or approximate P value? Gaussian Approximation 
P value summary *** 
Do the medians vary signif. (P < 0.05) Yes 
Number of groups 3 
Kruskal-Wallis statistic 25.82 
 
Number of 
values 
10 10 10 
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Minimum 49.30 39.30 21.60 
25% Percentile 50.38 41.60 23.95 
Median 53.30 42.05 27.70 
75% Percentile 57.35 44.33 28.30 
Maximum 58.40 46.00 33.00 
        
Mean 53.81 42.54 26.87 
Std. Deviation 3.340 1.922 3.153 
Std. Error 1.056 0.6079 0.9972 
        
Lower 95% CI 51.42 41.16 24.61 
Upper 95% CI 56.20 43.92 29.13 
 
